CUMULATIVE SUPPLEMENT 6
JAN'98-JUN'98



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

1998

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research, FDA

I

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Cumulative Supplement 6

JUNE 1998

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

CUMULATIVE SUPPLEMENT 6
JUNE 1998

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 18th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 18th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 19th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)

NO APPLICANT NAME CHANGES - JUNE 1998

1.3 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.4 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Alcon's NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.5 FOLLITROPIN ALFA AND BETA

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

1.6 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are available on Internet: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; Prescription and OTC Drug Product Patent and Exclusivity Data; and Appendices.

These files may be accessed on the Internet's World Wide Web. To access the CDER Home Page, use this Uniform Resource Locator (URL): http://www.fda gov/cder. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

The Prescription Drug Products and OTC Drug Product files will be available on a monthly basis in the near future.

1.7 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1997) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1997	MAR 1998	JUN 1998	SEP 1998
DRUG PRODUCTS LISTED	9624	9711	9768	
SINGLE SOURCE	2462 (25.6%)	2484 (25.6%)	2494 (25.6%)	
MULTISOURCE	7052 (73.3%)	7117 (73.3%)	7164 (73.3%)	
THERAPEUTICALLY EQUIVALENT	6673 (69.3%)	6746 (69.5%)	6790 (69.5%)	
NOT THERAPEUTICALLY EQUIVALENT	379 (4.0%)	371 (3.8%)	374 (3.8%)	
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	110 (1.1%)	
NEW MOLECULAR ENTITIES APPROVED	--	8	9	
NUMBER OF APPLICANTS	551	529	538	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACARBOSE

TABLET; ORAL
PRECOSE

# [redacted]	25MG	[redacted]	[redacted]
	25MG	N20482 004	MAY 29, 1997
			N20482 004
			MAY 29, 1997

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	ROYCE LABS	[redacted]	[redacted]
AA		[redacted]	[redacted]
AA		[redacted]	[redacted]
AA	WATSON LABS	300MG;15MG	DEC 28, 1994
AA		300MG;30MG	N89998 001
AA		300MG;60MG	DEC 28, 1994
			N89999 001
			DEC 28, 1994

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	+ MIKART	500MG/15ML;7.5MG/15ML	N81051 001
			AUG 28, 1992
AA	PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001
			MAR 13, 1998

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MALLINCKRODT	500MG;7.5MG	N40201 001
			FEB 27, 1998
AA		500MG;10MG	[redacted]
AA	ROYCE LABS	[redacted]	[redacted]
AA		[redacted]	[redacted]
AA		[redacted]	[redacted]

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	ROYCE LABS	[redacted]	[redacted]
AA		[redacted]	[redacted]
AA		[redacted]	[redacted]
AA	WATSON LABS	500MG;2.5MG	N40123 003
			MAR 04, 1996
AA		500MG;5MG	N40122 001
			MAR 04, 1996
AA		500MG;7.5MG	N40123 004
			MAR 04, 1996
AA		650MG;7.5MG	N40123 001
			MAR 04, 1996
AA		650MG;10MG	N40123 002
			MAR 04, 1996
AA		750MG;7.5MG	N40122 002
			MAR 04, 1996

ACETAMINOPHEN; OXYCODONE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	HALSEY	500MG;5MG	N40219 001
			JAN 22, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	ROYCE LABS	500MG;5MG	N40234 001
			OCT 30, 1997
AA	WATSON LABS	500MG;5MG	N40234 001
			OCT 30, 1997

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	DURAMED	325MG;5MG	N40272 001
			JUN 30, 1998
AA	ROYCE LABS	325MG;5MG	N40171 001
			OCT 30, 1997
AA	WATSON LABS	325MG;5MG	N40171 001
			OCT 30, 1997

> ADD >
> ADD >

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
PROPOXYPHENE HCL AND ACETAMINOPHEN

[redacted]	[redacted]	[redacted]	N40139 001 DEC 16, 1996
AA	WATSON LABS	650MG;65MG	N40139 001 DEC 16, 1996

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	B BRAUN	250MG/100ML	N18161 001
[redacted]	[redacted]	[redacted]	[redacted]

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB	CHELSEA LABS	200MG		N75101 001 APR 15, 1998
AB	GENPHARM	200MG	> ADD > > ADD >	N74977 001 APR 13, 1998

TABLET; ORAL
ACYCLOVIR

AB	COPLEY PHARM	400MG		N75021 001 MAR 18, 1998
AB		800MG		N75021 002 MAR 18, 1998
AB	GENPHARM	400MG	> ADD > > ADD >	N74976 001 APR 13, 1998
AB		800MG		N74976 002 APR 13, 1998
*	[redacted]	[redacted]		[redacted]
●		200MG		N74556 001 APR 22, 1997

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

AP	AESGEN	EQ 500MG BASE/VIAL	N75015 001 APR 30, 1998

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

AP	APOTHECON	EQ 500MG BASE/VIAL	N74897 001 FEB 27, 1998
AP		EQ 1GM BASE/VIAL	N74897 002 FEB 27, 1998
AP	FUJISAWA	EQ 500MG BASE/VIAL	N74930 001 MAY 13, 1998
AP		EQ 1GM BASE/VIAL	N74930 002 MAY 13, 1998

ADENOSINE

INJECTABLE; INJECTION
ADENOCARD

+	FUJISAWA HLTHCARE	3MG/ML	> ADD > > ADD >	N19937 002 OCT 30, 1989
*	[redacted]	[redacted]	> DLT > > DLT >	[redacted]

ADENOSCAN

+	FUJISAWA HLTHCARE	3MG/ML	> ADD > > ADD >	N20059 001 MAY 18, 1995
*	[redacted]	[redacted]	> DLT > > DLT >	[redacted]

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	BAUSCH AND LOMB	EQ 0.5% BASE		N75050 001 JUN 18, 1998
AN	HI TECH PHARMA	EQ 0.5% BASE		N74543 001 JAN 15, 1998

SYRUP; ORAL
ALBUTEROL SULFATE

AA	HI TECH PHARMA	EQ 2MG BASE/5ML	N74749 001 JAN 30, 1998
[redacted]	[redacted]	[redacted]	[redacted]
●		EQ 2MG BASE/5ML	N74302 001 SEP 30, 1994

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	GENEVA PHARMS	2MG	N74490 001
AB	[illegible]	[illegible]	[illegible]
AB		[illegible]	
AB		[illegible]	
AB	WATSON LABS	0.25MG	JAN 21, 1997
AB		0.5MG	N74479 002 JAN 21, 1997
AB		1MG	N74479 003 JAN 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL

AP	BEDFORD	0.5MG/ML	N74815 001 JAN 20, 1998

PROSTIN VR PEDIATRIC

AP	+ PHARMACIA AND UPJOHN	0.5MG/ML	N18484 001
	[illegible]	[illegible]	[illegible]

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
SYMMETREL

[illegible]	[illegible]	[illegible]	[illegible]
AA	+ ENDO PHARMS	50MG/5ML	N16023 002

TABLET; ORAL
SYMMETREL

	[illegible]	[illegible]	[illegible]
	+	100MG	N18101 001

AMCINONIDE

OINTMENT; TOPICAL
CYCLOCORT

	[illegible]	[illegible]	[illegible]

AMCINONIDE

OINTMENT; TOPICAL
CYCLOCORT

	+ WYETH AYERST	0.1%	N18498 001

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE

[illegible]	[illegible]	[illegible]	[illegible]
AB	WATSON LABS	EQ 5MG ANHYDROUS;50MG	N73334 001 JUL 19, 1991

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
CORDARONE

AB	+ WYETH AYERST	200MG	N18972 001 DEC 24, 1985

PACERONE

AB	UPSHER SMITH	200MG	N75135 001 APR 30, 1998

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

AB	[illegible]	[illegible]	[illegible]
AB		[illegible]	
AB		[illegible]	
AB		[illegible]	
AB	WATSON LABS	10MG;2MG	OCT 17, 1991
AB		10MG;4MG	N73009 001 OCT 17, 1991
AB		25MG;2MG	N73008 001 OCT 17, 1991
AB		25MG;4MG	N73010 001 OCT 17, 1991

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
AMMONIUM CHLORIDE 2.14%

	@	B BRAUN	40MEQ/100ML	N85734 001
	#	MCGAW	40MEQ/100ML	N85734 001

AMRINONE LACTATE

INJECTABLE; INJECTION
INOCOR

		SANOFI	EQ 5MG BASE/ML	N18700 001 JUL 31, 1984
	+		EQ 5MG BASE/ML	N18700 001 JUL 31, 1984

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
GENESA

	#	GENSIA	0.05MG/ML	N20420 001 SEP 12, 1997
	+	GENSIA AUTOMEDICS	0.05MG/ML	N20420 001 SEP 12, 1997

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENGESIC

AB		PAR PHARM	385MG;30MG;25MG	N75141 001 MAY 29, 1998

ORPHENGESIC FORTE

AB		PAR PHARM	770MG;60MG;50MG	N75141 002 MAY 29, 1998

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
OXYCODONE AND ASPIRIN

AA		WATSON LABS	325MG;4.5MG;0.38MG	N40255 001 FEB 27, 1998

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE

AB		MARTEC	50MG;25MG	N74404 001 MAY 14, 1998
AB			100MG;25MG	N74404 002 MAY 14, 1998

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR

		PARKE DAVIS	EQ 10MG BASE	N20702 001 DEC 17, 1996
			EQ 20MG BASE	N20702 002 DEC 17, 1996
	#		EQ 40MG BASE	N20702 003 DEC 17, 1996
		WARNER LAMBERT EXPOR	EQ 10MG BASE	N20702 001 DEC 17, 1996
			EQ 20MG BASE	N20702 002 DEC 17, 1996
	+		EQ 40MG BASE	N20702 003 DEC 17, 1996

BACITRACIN

POWDER, FOR RX COMPOUNDING
BACITRACIN

		PADDOCK	5,000,000 UNITS/BOT	N62456 001 JUL 27, 1983
	@		5,000,000 UNITS/BOT	N62456 001 JUL 27, 1983

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOSPORIN

AT	#	GLAXO WELLCOME	400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50417 002
AT	+	MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50417 001

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

[redacted]		[redacted]		[redacted]
AT		AKORN	500 UNITS/GM; 10,000 UNITS/GM	N64028 001 JAN 30, 1995
		POLYSPORIN		
[redacted]	*	[redacted]	[redacted]	[redacted]
AT	+	MONARCH PHARMS	500 UNITS/GM; 10,000 UNITS/GM	N61229 001

BACLOFEN

TABLET; ORAL
BACLOFEN

[redacted]		[redacted]	[redacted]	[redacted]
[redacted]			[redacted]	[redacted]
AB		WATSON LABS	10MG	N73092 001 JAN 28, 1994
AB			20MG	N73093 001 JAN 28, 1994

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
VASCOR

		[redacted]	[redacted]	[redacted]
	*		[redacted]	[redacted]
	+		300MG	N19002 002 DEC 28, 1990
	●		400MG	N19002 003 DEC 28, 1990

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE

[redacted]		[redacted]	[redacted]	[redacted]
	●		EQ 0.1% BASE	N70053 001 JUN 10, 1986

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC
AZOPT

	+	ALCON	1%	N20815 001 APR 01, 1998

BROMOCRIPTINE MESYLATE

TABLET; ORAL
BROMOCRIPTINE MESYLATE

AB		LEK PHARM	EQ 2.5MG BASE	N74631 001 JAN 13, 1998
		PARLODEL		
AB	+	NOVARTIS	EQ 2.5MG BASE	N17962 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

		B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML	N19864 001 JUN 10, 1993
		[redacted]	[redacted]	[redacted]

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML N19867 001 DEC 20, 1993
[redacted]

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER
AP B BRAUN 33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML N18256 001
AP 33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML N20000 001 APR 17, 1992
[redacted]

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER
● B BRAUN 20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML N17510 001
[redacted]

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER
B BRAUN 35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML N19718 001 SEP 29, 1989
[redacted]

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC
PLEGISOL IN PLASTIC CONTAINER
[redacted]

SOLUTION; PERFUSION/CARDIAC
PLEGISOL IN PLASTIC CONTAINER
+ ABBOTT 17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML N18608 001 FEB 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER
AP B BRAUN 33MG/100ML;30MG/100ML; 860MG/100ML N18721 001 NOV 09, 1982
AP 33MG/100ML;30MG/100ML; 860MG/100ML N20002 001 APR 17, 1992
[redacted]

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	33MG/100ML;30MG/100ML; 860MG/100ML		N18156 001
AB	[redacted]	[redacted]		[redacted]

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML		N19632 001 FEB 29, 1988
	●	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML		N18023 001
AB	[redacted]	[redacted]		[redacted]
	●	[redacted]		[redacted]

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML		N18681 001 DEC 27, 1982
AB	[redacted]	[redacted]		[redacted]

> ADD > **CANDESARTAN CILEXETIL**

> ADD > TABLET; ORAL
> ADD > ATACAND

> ADD >	ASTRA MERCK	4MG	N20838 001 JUN 04, 1998
> ADD >		8MG	N20838 002 JUN 04, 1998
> ADD >		16MG	N20838 003 JUN 04, 1998
> ADD >	◆	32MG	N20838 004 JUN 04, 1998

CAPECITABINE

TABLET; ORAL
XELODA

	ROCHE	150MG	N20896 001 APR 30, 1998
◆		500MG	N20896 002 APR 30, 1998

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

[redacted]	[redacted]	[redacted]	[redacted]
AB	WATSON LABS	12.5MG	N74451 001 FEB 13, 1996
AB		25MG	N74451 002 FEB 13, 1996
AB		50MG	N74451 003 FEB 13, 1996
AB		100MG	N74451 004 FEB 13, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPOZIDE 25/15

> ADD >	AB	BRISTOL MYERS SQUIBB	25MG;15MG	N18709 001 OCT 12, 1984
> ADD > > DLT >	AB	[redacted]	[redacted]	[redacted]

CAPOZIDE 25/25

> ADD >	AB	◆ BRISTOL MYERS SQUIBB	25MG;25MG	N18709 002 OCT 12, 1984
> ADD > > DLT >	AB	[redacted]	[redacted]	[redacted]

CAPOZIDE 50/15

> ADD >	AB	◆ BRISTOL MYERS SQUIBB	50MG;15MG	N18709 004 OCT 12, 1984

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 50/15

> DLT >	AB	*	[redacted]	[redacted]	[redacted]
> DLT					OCT 12, 1984

CAPOZIDE 50/25

> ADD >	AB		BRISTOL MYERS SQUIBB	50MG;25MG	N18709 003
> ADD >					OCT 12, 1984
> DLT >	AB		[redacted]	[redacted]	[redacted]
> DLT >					[redacted]

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

> ADD >	AB		ZENITH GOLDLINE	25MG;15MG	N75055 001
> ADD >					JUN 18, 1998
> ADD >	AB			25MG;25MG	N75055 002
> ADD >					JUN 18, 1998
> ADD >	AB			50MG;15MG	N75055 004
> ADD >					JUN 18, 1998
> ADD >	AB			50MG;25MG	N75055 003
> ADD >					JUN 18, 1998

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

	*	[redacted]	200MG	[redacted]
				[redacted]
	*		300MG	[redacted]
				[redacted]
	+	SHIRE	200MG	N20712 001
				SEP 30, 1997
	+		300MG	N20712 002
				SEP 30, 1997

CARBIDOPA

TABLET; ORAL

LODOSYN

	+	DUPONT MERCK	25MG	N17830 001
	*	[redacted]	[redacted]	[redacted]

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

AB		DUPONT MERCK	10MG;100MG	N17555 001

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

AB		DUPONT MERCK	25MG;100MG	N17555 003
AB	+		25MG;250MG	N17555 002
[redacted]		[redacted]	[redacted]	[redacted]
[redacted]			[redacted]	[redacted]
[redacted]	*		[redacted]	[redacted]

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

		DUPONT MERCK	25MG;100MG	N19856 002
				DEC 24, 1992
	+		50MG;200MG	N19856 001
				MAY 30, 1991
		[redacted]	[redacted]	[redacted]
				[redacted]
	*		[redacted]	[redacted]
				[redacted]

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

[redacted]		[redacted]	[redacted]	[redacted]
				[redacted]
AA		WATSON LABS	350MG	N40152 001
				DEC 03, 1996

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL

CEFACLOR

AB	MARSAM	EQ 125MG BASE/5ML	N64204 001
			FEB 18, 1998
AB		EQ 187MG BASE/5ML	N64205 001
			FEB 18, 1998
AB		EQ 250MG BASE/5ML	N64206 001
			FEB 18, 1998
AB		EQ 375MG BASE/5ML	N64207 001
			FEB 18, 1998

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP		FUJISAWA	EQ 10GM BASE/VIAL	N64170 001 MAR 18, 1998
AP			EQ 20GM BASE/VIAL	N64170 002 MAR 18, 1998

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEPIZOX

> DLT >	*	FUJISAWA	EQ 500MG BASE/VIAL	N50560 001 SEP 15, 1983
> DLT >	*		EQ 1GM BASE/VIAL	N50560 002 SEP 15, 1983
> DLT >	*		EQ 2GM BASE/VIAL	N50560 003 SEP 15, 1983
> DLT >			EQ 10GM BASE/VIAL	N50560 005 MAR 19, 1993
> ADD >	+	FUJISAWA HLTHCARE	EQ 500MG BASE/VIAL	N50560 001 SEP 15, 1983
> ADD >	+		EQ 1GM BASE/VIAL	N50560 002 SEP 15, 1983
> ADD >	+		EQ 2GM BASE/VIAL	N50560 003 SEP 15, 1983
> ADD >			EQ 10GM BASE/VIAL	N50560 005 MAR 19, 1993

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

> DLT >	*	FUJISAWA	EQ 40MG BASE/ML	N50589 002 OCT 03, 1984
> ADD >	*	FUJISAWA HLTHCARE	EQ 40MG BASE/ML	N50589 002 OCT 03, 1984

CEFIZOX IN PLASTIC CONTAINER

> DLT >	*	FUJISAWA	EQ 20MG BASE/ML	N50589 003 APR 13, 1995
> DLT >	*		EQ 40MG BASE/ML	N50589 004 APR 13, 1995
> ADD >	+	FUJISAWA HLTHCARE	EQ 20MG BASE/ML	N50589 003 APR 13, 1995
> ADD >	+		EQ 40MG BASE/ML	N50589 004 APR 13, 1995

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME

AB		ASTRA PHARMS	EQ 750MG BASE/VIAL	N64192 002 APR 16, 1998
AP			EQ 1.5GM BASE/VIAL	N64192 001 APR 16, 1998
AP			EQ 7.5GM BASE/VIAL	N64191 001 APR 16, 1998

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

> ADD >	AB	ZENITH GOLDLINE	EQ 250MG BASE	N61969 001
> ADD >	AB		EQ 500MG BASE	N61969 002
> DLT >	AB	ZENITH LABS	EQ 250MG BASE	N61969 001
> DLT >	AB		EQ 500MG BASE	N61969 002

POWDER FOR RECONSTITUTION; ORAL
KEFLEX

	*	LILLY	EQ 100MG BASE/ML	N50406 003
			EQ 100MG BASE/ML	N62117 001
	@		EQ 100MG BASE/ML	N50406 003
	+		EQ 100MG BASE/ML	N62117 001

CHLORAMPHENICOL

CAPSULE; ORAL
CHLOROMYCETIN

AB	*	PARKE DAVIS	250MG	N60531 002
			50MG	N60531 001
	*		100MG	N60531 003
AB	+	PARKEDALE	250MG	N60591 002
			50MG	N60591 001
	+		100MG	N60591 003

OINTMENT; OPHTHALMIC
CHLOROMYCETIN

AT	*	PARKE DAVIS	1%	N50156 001
AT	+	PARKEDALE	1%	N50156 001

POWDER FOR RECONSTITUTION; OPHTHALMIC
CHLOROMYCETIN

	*	PARKE DAVIS	25MG/VIAL	N50143 001
	+	PARKEDALE	25MG/VIAL	N50143 001

CHLORAMPHENICOL

SOLUTION/DROPS; OPHTHALMIC
OPHTHOCHLOR

AB	[redacted]	[redacted]	[redacted]
AT	PARKEDALE	0.5%	N61220 001

SOLUTION/DROPS; OTIC
CHLOROMYCETIN

*	[redacted]	[redacted]	[redacted]
+	PARKEDALE	0.5%	N50205 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

POWDER FOR RECONSTITUTION; OPHTHALMIC
CHLOROMYCETIN HYDROCORTISONE

*	[redacted]	[redacted]	[redacted]
+	PARKEDALE	12.5MG/VIAL;25MG/VIAL	N50202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT

*	[redacted]	[redacted]	[redacted]
	PARKEDALE	10MG/GM;5MG/GM; 10,000 UNITS/GM	N50201 002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
CHLOROMYCETIN

AP	*	[redacted]	[redacted]	[redacted]
AP	+	PARKEDALE	EQ 1GM BASE/VIAL	N50155 001

CHLORDIAZEPOXIDE

TABLET; ORAL
LIBRITABS

	+ ICN	5MG	N85482 001
		10MG	N85481 001
		25MG	N85488 001
	* [redacted]	[redacted]	[redacted]
		[redacted]	[redacted]
		[redacted]	[redacted]

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
LIBRIUM

AB	ICN	5MG	N85461 001
AB		10MG	N85472 001
AB	+	25MG	N85475 001
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
[redacted]	*	[redacted]	[redacted]

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
PERIDEX

[redacted]	* [redacted]	[redacted]	[redacted]
AT	+ ZILA	0.12%	N19028 001 AUG 13, 1986

TABLET; DENTAL
PERIOCHIP

	+ PERIO PRODS (IS)	2.5MG	N20774 001 MAY 15, 1998

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL

AP	[redacted]	[redacted]	[redacted]
		25MG/ML	N89563 001 APR 15, 1988

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

AA	[redacted]	[redacted]	[redacted]
AA	WATSON LABS	500MG	N81040 001 AUG 22, 1989

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	NOVOPHARM	EQ 4GM RESIN/PACKET	N74347 001	MAY 28, 1998
AB		EQ 4GM RESIN/SCOOPFUL	N74347 002	MAY 28, 1998
	CHOLESTYRAMINE LIGHT			
AB	NOVOPHARM	EQ 4GM RESIN/PACKET	N74348 001	MAY 28, 1998
AB		EQ 4GM RESIN/SCOOPFUL	N74348 002	MAY 28, 1998
	LOCHOLEST			
AB	EON	EQ 4GM RESIN/PACKET	N74561 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74561 002	AUG 15, 1996
	[redacted]	[redacted]	[redacted]	[redacted]
	[redacted]	[redacted]	[redacted]	[redacted]
	LOCHOLEST LIGHT			
AB	EON	EQ 4GM RESIN/PACKET	N74562 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74562 002	AUG 15, 1996
	[redacted]	[redacted]	[redacted]	[redacted]
	[redacted]	[redacted]	[redacted]	[redacted]

CIMETIDINE

SOLUTION; ORAL

		CIMETIDINE HCL			
> ADD >	AA	DURAMED	300MG/5ML	N75110 001	JUN 18, 1998
> ADD >					

TABLET; ORAL

	CIMETIDINE			
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]		
[redacted]		[redacted]		

CIMETIDINE

TABLET; ORAL

	CIMETIDINE			
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AB	ZENITH LABS	200MG	N74424 001	JUL 28, 1995
AB		300MG	N74424 002	JUL 28, 1995
AB		400MG	N74424 003	JUL 28, 1995
AB		800MG	N74424 004	JUL 28, 1995

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

	CILOXAN			
+	ALCON	EQ 0.3% BASE	N20369 001	MAR 30, 1998

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

	CIPRO HC			
+	BAYER	EQ 0.2% BASE;1%	N20805 001	FEB 10, 1998

CLEMASTINE FUMARATE

SYRUP; ORAL

	CLEMASTINE FUMARATE			
AA	MORTON GROVE	EQ 0.5MG BASE/5ML	N74863 001	MAR 13, 1998

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

	CLEOCIN 3			
+	PHARMACIA AND UPJOHN	EQ 2% BASE	N50680 002	MAR 02, 1998

INJECTABLE; INJECTION

	CLINDAMYCIN PHOSPHATE			
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

	CLINDAMYCIN PHOSPHATE		
	@ MARSAM	EQ 150MG BASE/ML	N62913 001 OCT 20, 1988

SOLUTION; TOPICAL

	CLEOCIN T		
[redacted]	[redacted]	[redacted]	[redacted]
	@	EQ 1% BASE	N62363 001 FEB 08, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	CLOMIPRAMINE HCL		
AB	MYLAN	25MG	N74947 001 APR 30, 1998
AB		50MG	N74947 002 APR 30, 1998
AB		75MG	N74947 003 APR 30, 1998

CLONAZEPAM

[redacted]

TABLET, ORALLY DISINTEGRATING; ORAL

	KLONOPIN RAPIDLY DISINTEGRATING		
	+ ROCHE	0.125MG	N20813 001 DEC 23, 1997
		0.25MG	N20813 002 DEC 23, 1997

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING; ORAL

	KLONOPIN RAPIDLY DISINTEGRATING		
	ROCHE	0.5MG	N20813 003 DEC 23, 1997
		1MG	N20813 004 DEC 23, 1997
	+	2MG	N20813 005 DEC 23, 1997

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

	COLY-MYCIN M		
	[redacted]	[redacted]	[redacted]
	+ PARKEDALE	EQ 150MG BASE/VIAL	N50108 002

CORTICOTROPIN

INJECTABLE; INJECTION

	ACTH		
	[redacted]	[redacted]	[redacted]
	@ PARKEDALE	25 UNITS/VIAL	N08317 002
	@	40 UNITS/VIAL	N08317 004

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC

	CROLOM		
AT	BAUSCH AND LOMB	4%	N74443 001 JAN 30, 1995
	[redacted]	[redacted]	[redacted]
	CROMOLYN SODIUM		
AT	ADV REMEDIES	4%	N74706 001 APR 29, 1998
	OPTICROM		
AT	+ ALLERGAN	4%	N18155 001 OCT 03, 1984
	[redacted]	[redacted]	[redacted]

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL

[redacted]				[redacted]
AB	WATSON LABS	10MG		N74436 001 NOV 30, 1994

DACTINOMYCIN

INJECTABLE; INJECTION
COSMEGEN

+	MERCK	0.5MG/VIAL	N50682 001
[redacted]			

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN

[redacted]			
+		10,000 IU/ML	N20287 004 JAN 30, 1998

DANAZOL

CAPSULE; ORAL
DANAZOL

AB	BARR	50MG	N74582 003 MAY 29, 1998
AB		100MG	N74582 002 MAY 29, 1998

DANOCRINE

AB	SANOFI	50MG	N17557 003
AB		100MG	N17557 004

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL PRESERVATIVE FREE

>ADD>	AP	+ BEDFORD	EQ 20MG BASE/VIAL	N50731 001 JAN 30, 1998
>ADD>	AP	GENSIA SICOR PHARMS	EQ 20MG BASE/VIAL	N64212 001 JUN 23, 1998

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
MIRCETTE

+	ORGANON	0.15MG;0.02MG	N20713 001 APR 22, 1998

DESOXIMETASONE

OINTMENT; TOPICAL
DESOXIMETASONE

AB	ALTANA	0.25%	N73440 001 APR 01, 1998

DEXAMETHASONE SODIUM PHOSPHATE

[redacted]

[redacted]			
●		EQ 0.1MG PHOSPHATE/INH	N13413 001
[redacted]			
●		EQ 0.1MG PHOSPHATE/INH	N14242 001

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 10% IN PLASTIC CONTAINER

AP	B BRAUN	10GM/100ML	N18046 001
[redacted]			

DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML	N16730 001
AP		50MG/ML	N16730 002
[redacted]			

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19873 001 JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER
[redacted] [redacted] [redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML N19844 001 JUN 10, 1993
[redacted] [redacted] [redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML N19843 001 AUG 09, 1993
AP [redacted] [redacted] [redacted]

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML N18274 001
AP [redacted] [redacted] [redacted]

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML;75MG/100ML N18744 001 NOV 09, 1982
AP [redacted] [redacted] [redacted]

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML N19870 001 JUN 10, 1993
[redacted] [redacted] [redacted]

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
● B BRAUN 10GM/100ML;900MG/100ML N18047 001
● [redacted] [redacted] [redacted]
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
● B BRAUN 5GM/100ML;900MG/100ML N18026 001
● [redacted] [redacted] [redacted]

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM
AP [redacted] [redacted] [redacted]
● 5MG/ML N72371 001 JAN 29, 1993

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

	DICLOFENAC SODIUM			
AB	ALCON	0.1%	†	N20809 001 MAY 04, 1998
	VOLTAREN			
AB	+ CIBA	0.1%		N20037 001 MAR 28, 1991

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL

	DICYCLOMINE HCL			
[redacted]	[redacted]	[redacted]		[redacted]
	●	20MG		N84600 001 JUL 29, 1985

DIFLORASONE DIACETATE

CREAM; TOPICAL

	DIFLORASONE DIACETATE			
AB	ALTANA	0.05%		N75187 001 MAR 30, 1998
	PSORCON			
AB	+ DERMIK LABS	0.05%		N20205 001 NOV 20, 1992
[redacted]	[redacted]	[redacted]		[redacted]

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DILTIAZEM HCL			
AB2	MYLAN	120MG		N75124 002 MAR 18, 1998
AB2		180MG		N75124 003 MAR 18, 1998
AB2		240MG		N75124 001 MAR 18, 1998
	TIAZAC			
[redacted]	[redacted]	[redacted]		[redacted]
BC	+	120MG		N20401 001 SEP 11, 1995

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	TIAZAC			
[redacted]	[redacted]	[redacted]		[redacted]
BC	+	180MG		N20401 002 SEP 11, 1995
[redacted]	[redacted]	[redacted]		[redacted]
BC	+	240MG		N20401 003 SEP 11, 1995
[redacted]	[redacted]	[redacted]		[redacted]
BC	+	300MG		N20401 004 SEP 11, 1995
[redacted]	[redacted]	[redacted]		[redacted]
	+	360MG		N20401 005 SEP 11, 1995

INJECTABLE; INJECTION

	DILTIAZEM HCL			
AP	ABBOTT	5MG/ML		N74941 001 APR 15, 1998
AP	TAYLOR PHARMA	5MG/ML		N75086 001 APR 09, 1998

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

	DIPHENHYDRAMINE HCL			
[redacted]	[redacted]	[redacted]		[redacted]
	●	12.5MG/5ML		N83237 001 JAN 25, 1982

DIPYRIDAMOLE

INJECTABLE; INJECTION

	DIPYRIDAMOLE			
AP	BEDFORD	5MG/ML		N74939 001 APR 13, 1998

† SEE SECTION 1.4 OF INTRODUCTION

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE

>DLT>		@ [redacted]	[redacted]	[redacted]	[redacted]
>DLT>					[redacted]

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

>ADD>	AP	LUITPOLD	EQ 12.5MG BASE/ML	N74545 001	JUN 25, 1998
>ADD>	AP	MARSAM	EQ 12.5MG BASE/ML	N74279 001	FEB 18, 1998
	AP		EQ 12.5MG BASE/ML	N74995 001	MAR 31, 1998

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
COSOPT

	+	MERCK	EQ 2% BASE;EQ 0.5% BASE	N20869 001 APR 07, 1998

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HCL

[redacted]		[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]
AB		WATSON LABS	EQ 10MG BASE	[redacted]
AB			EQ 25MG BASE	N72986 001 MAR 29, 1991
AB			EQ 50MG BASE	N72987 001 MAR 29, 1991

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
RUBEX

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AP		BRISTOL MYERS SQUIBB	10MG/VIAL	N62926 001 APR 13, 1989
AP			50MG/VIAL	N62926 002 APR 13, 1989
			100MG/VIAL	N62926 003 APR 13, 1989

DYPHYLLINE

>DLT>	[redacted]			
>DLT>	[redacted]			
>DLT>		# [redacted]	[redacted]	[redacted]
>ADD>		@	250MG/ML	N09088 001

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE

AP		ABBOTT	10MG/ML	N40131 001 FEB 24, 1998

ENCAINIDE HYDROCHLORIDE

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
		@	25MG	N18981 002 DEC 24, 1986
		@	35MG	N18981 003 DEC 24, 1986

ENOXAPARIN SODIUM

INJECTABLE; INJECTION
LOVENOX

+	RHONE POULENC RORER	40MG/0.4ML	N20164 002	JAN 30, 1998
+		60MG/0.6ML	N20164 003	MAR 27, 1998
+		80MG/0.8ML	N20164 004	MAR 27, 1998
+		100MG/ML	N20164 005	MAR 27, 1998

EPTIFIBATIDE

> DLT >
> DLT >

INJECTABLE; INJECTION
INTEGRILIN

+	COR	75MG/100ML	N20718 002	MAY 18, 1998
+		2MG/ML	N20718 001	MAY 18, 1998

ERYTHROMYCIN

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AT	AKORN	0.5%	N64030 001	JUL 18, 1996

OINTMENT; TOPICAL
AKNE-MYCIN

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
+	EM INDS	2%	N50584 001	JAN 10, 1985

TABLET, DELAYED RELEASE; ORAL
E-MYCIN

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AB		333MG	N60272 002	

ERY-TAB

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AB	+	250MG	N62298 001	
[redacted]		[redacted]	[redacted]	[redacted]

ERYTHROMYCIN

TABLET, DELAYED RELEASE; ORAL
ERY-TAB

AB	+ ABBOTT	333MG	N62298 003	MAR 29, 1982
[redacted]		[redacted]	[redacted]	[redacted]
AB	+	500MG	N62298 002	

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL
ERYTHROMYCIN ETHYLSUCCINATE

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

+	BAXTER PHARM PROD	10MG/ML	N19386 001	AUG 15, 1988
[redacted]		100MG/ML	N19386 003	DEC 31, 1986
+		250MG/ML	N19386 002	DEC 31, 1986
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]

ESTAZOLAM

TABLET; ORAL
ESTAZOLAM

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]
AB	WATSON LABS	1MG	N74818 001	AUG 19, 1997
AB		2MG	N74818 002	AUG 19, 1997

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA

BX	+	BERLEX	0.075MG/24HR	N20375 003 MAR 23, 1998

TABLET; ORAL
ESTRADIOL

AB	ENDEAVOR	0.5MG	N40138 001 JAN 30, 1998
AB		1MG	N40138 002 JAN 30, 1998
AB		2MG	N40138 003 JAN 30, 1998

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION
DEPO-ESTRADIOL

	[redacted]	[redacted]	[redacted]
		[redacted]	[redacted]
	●	1MG/ML	N85470 001
	●	3MG/ML	N85470 002

ESTRADIOL VALERATE

INJECTABLE; INJECTION
DELESTROGEN

> ADD >	AQ	+ BRISTOL MYERS SQUIBB	20MG/ML	N09402 004
> ADD >	AQ	+	40MG/ML	N09402 003
> ADD >		+	10MG/ML	N09402 002
> DLT >	[redacted]	[redacted]	[redacted]	[redacted]
> DLT >	[redacted]	[redacted]	[redacted]	[redacted]
> DLT >		[redacted]	[redacted]	[redacted]

ESTRONE

INJECTABLE; INJECTION
THELIN

	[redacted]	[redacted]	[redacted]
		[redacted]	[redacted]
		[redacted]	[redacted]
	● PARKEDALE	1MG/ML	N03977 001
	●	2MG/ML	N03977 002
	●	5MG/ML	N03977 003

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
LEVORA 0.15/30-21

[redacted]	[redacted]	[redacted]	[redacted]
AB	WATSON LABS	0.03MG;0.15MG	N73592 001 DEC 13, 1993

TABLET; ORAL-28
LEVORA 0.15/30-28

[redacted]	[redacted]	[redacted]	[redacted]
AB	WATSON LABS	0.03MG;0.15MG	N73594 001 DEC 13, 1993

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/35E-21

[redacted]	[redacted]	[redacted]	[redacted]
AB	SEARLE	0.035MG;1MG	N71480 001 APR 12, 1988

TABLET; ORAL-28
NORETHIN 1/35E-28

[redacted]	[redacted]	[redacted]	[redacted]
AB	SEARLE	0.035MG;1MG	N71481 001 APR 12, 1988

ETODOLAC

CAPSULE; ORAL
ETODOLAC

AB	AESGEN	300MG	N74929 001 JAN 30, 1998
AB	TARO	200MG	N75078 001 APR 30, 1998
AB		300MG	N75078 002 APR 30, 1998

TABLET; ORAL
ETODOLAC

AB	CHELSEA LABS	400MG	N75069 001 APR 16, 1998

ETODOLAC

TABLET; ORAL
ETODOLAC

AB	MYLAN	400MG	N75104 001 FEB 06, 1998
[redacted]	[redacted]	[redacted]	[redacted]
AB	TARO	400MG	N75074 001 MAR 11, 1998
AB	WATSON LABS	400MG	N74892 001 APR 16, 1997

TABLET, EXTENDED RELEASE; ORAL
LODINE XL

+	WYETH AYERST	500MG	N20584 003 JAN 20, 1998

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP	MARSAM	20MG/ML	N74968 001 JAN 09, 1998

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION
[redacted]

[redacted]	[redacted]	[redacted]	[redacted]

ETOPOPHOS PRESERVATIVE FREE

+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996
+		EQ 500MG BASE/VIAL	N20906 001 FEB 27, 1998

FAMOTIDINE

TABLET, ORALLY DISINTEGRATING; ORAL
PEPCID RPD

	MERCK	20MG	N20752 001 MAY 28, 1998
+		40MG	N20752 002 MAY 28, 1998

FENFLURAMINE HYDROCHLORIDE

[redacted]

[redacted]	[redacted]	[redacted]	[redacted]
@		20MG	N16618 001

FENOFIBRATE

CAPSULE; ORAL
LIPIDIL

@	ABBOTT	100MG	N19304 001 DEC 31, 1993
[redacted]	[redacted]	[redacted]	[redacted]

TRICOR (MICRONIZED)

+	ABBOTT	67MG	N19304 002 FEB 09, 1998

FENTANYL CITRATE

INJECTABLE; INJECTION
[redacted]

AP	[redacted]	[redacted]	[redacted]
AP	[redacted]	[redacted]	[redacted]

FENTANYL CITRATE PRESERVATIVE FREE

AP	ABBOTT	EQ 0.05MG BASE/ML	N72786 001 SEP 24, 1991
AP	+ ELKINS SINN	EQ 0.05MG BASE/ML	N19101 001 JUL 11, 1984
AP	MARSAM	EQ 0.05MG BASE/ML	N74917 001 FEB 03, 1998
[redacted]	[redacted]	[redacted]	[redacted]

SUBLIMAZE PRESERVATIVE FREE

AP	+ JANSSEN	EQ 0.05MG BASE/ML	N16619 001

FLOSEQUINAN

[redacted]

[redacted]	[redacted]	[redacted]	[redacted]

FLOSEQUINAN

TABLET; ORAL
MANUFLAN
EXCEL PHARM 75MG [illegible]
* 100MG [illegible]
● 50MG N19960 001 DEC 30, 1992
● 75MG N19960 002 DEC 30, 1992
● 100MG N19960 003 DEC 30, 1992

FLUOROURACIL

INJECTABLE; INJECTION
ADRUCIL
AP PHARMACIA AND UPJOHN 50MG/ML [illegible]
AP + 50MG/ML N81225 001 AUG 28, 1991

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
FLUPHENAZINE DECANOATE
AO KING PHARMS 25MG/ML N74966 001 APR 16, 1998

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
CORTISPORIN
* LILLY [illegible]
● 0.05%;EQ 3.5MG BASE/GM N50346 001

OINTMENT; TOPICAL
CORTISPORIN
* LILLY [illegible]
● 0.05%;EQ 3.5MG BASE/GM N50345 001

FLUVOXAMINE MALEATE

TABLET; ORAL
LUVOX
● SOLVAY 25MG [illegible]
25MG N20243 001 DEC 05, 1994

GEMFIBROZIL

CAPSULE; ORAL
LOPID
● PARKE DAVIS 200MG [illegible]
● 300MG [illegible]
● PARKE DAVIS PHARMS 200MG N18422 001
● 300MG N18422 002

TABLET; ORAL
LOPID
AB * PARKE DAVIS 600MG [illegible]
AB + PARKE DAVIS PHARMS 600MG N18422 003 NOV 20, 1986

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN EQ 40MG BASE/100ML N62814 008 AUG 28, 1987
AP EQ 60MG BASE/100ML N62814 009 AUG 28, 1987
AP EQ 70MG BASE/100ML N62814 010 AUG 28, 1987
AP EQ 0.8MG BASE/ML N62814 001 AUG 28, 1987
AP EQ 80MG BASE/100ML N62814 011 AUG 28, 1987
AP EQ 90MG BASE/100ML N62814 012 AUG 28, 1987
AP EQ 100MG BASE/100ML N62814 013 AUG 28, 1987
AP EQ 1.2MG BASE/ML N62814 002 AUG 28, 1987

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	EQ 120MG BASE/100ML	N62814 014 AUG 28, 1987
AP		EQ 1.4MG BASE/ML	N62814 003 AUG 28, 1987
AP		EQ 1.6MG BASE/ML	N62814 004 AUG 28, 1987
AP		EQ 1.8MG BASE/ML	N62814 005 AUG 28, 1987
AP		EQ 2MG BASE/ML	N62814 006 AUG 28, 1987
AP		EQ 2.4MG BASE/ML	N62814 007
AP	MCGAW	[redacted]	[redacted]
AP		[redacted]	[redacted]
AP		[redacted]	[redacted]
AP		[redacted]	[redacted]
AP		[redacted]	[redacted]
AP		[redacted]	[redacted]
AP		[redacted]	[redacted]
AP		[redacted]	[redacted]
AP		[redacted]	[redacted]
AP		[redacted]	[redacted]
AP		[redacted]	[redacted]
AP		[redacted]	[redacted]
AP		[redacted]	[redacted]
AP		[redacted]	[redacted]

> ADD > GLUCAGON HYDROCHLORIDE RECOMBINANT

> ADD > INJECTABLE; INJECTION
> ADD > GLUCAGEN
> ADD > + NOVO NORDISK EQ 1MG BASE/VIAL N20918 001
> ADD > JUN 22, 1998

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

> ADD >	AB	INVAMED	1.5MG	N75174 001
> ADD >				JUN 22, 1998
> ADD >	AB		3MG	N75174 002
> ADD >				JUN 22, 1998
> ADD >	AB	MYLAN	1.5MG	N74792 001
> ADD >				JUN 26, 1998
> ADD >	AB		3MG	N74792 002
> ADD >				JUN 26, 1998

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOSPORIN

AT	# [redacted]	[redacted]	[redacted]
AT	+ MONARCH PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N60582 001

GRANISETRON HYDROCHLORIDE

TABLET; ORAL
KYTRIL

> ADD >	@ SMITHKLINE BEECHAM	EQ 2MG BASE	N20305 002
> ADD >			JUN 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
RAXAR

# [redacted]	EQ 200MG BASE	[redacted]
	EQ 200MG BASE	N20695 001 NOV 06, 1997

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
RAXAR

	GLAXO WELLCOME	EQ 400MG BASE	N20695 002 MAY 14, 1998
+		EQ 600MG BASE	N20695 003 MAY 14, 1998

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HCL

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
AB	WATSON LABS	EQ 1MG BASE	N74762 001 JUN 25, 1997
AB		EQ 2MG BASE	N74762 002 JUN 25, 1997

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

[redacted]	[redacted]	[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	
●		0.5MG	NOV 03, 1986	
●		1MG	N71072 001 NOV 03, 1986	
●		2MG	N71073 001 NOV 03, 1986	> DLT >
●		5MG	N71074 001 NOV 03, 1986	> DLT > > DLT >

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

●	PUREPAC PHARM	10MG	N71075 001 AUG 04, 1987
●		20MG	N71076 001 AUG 04, 1987

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AQ	BEDFORD	EQ 50MG BASE/ML	N74811 001 JAN 30, 1998

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
●		EQ 5MG BASE/ML	N72516 001 FEB 25, 1993
●		EQ 5MG BASE/ML	N72517 001 FEB 25, 1993

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	200 UNITS/100ML	N19953 001 JUL 20, 1992
●		200 UNITS/100ML	N19042 001 MAR 29, 1985
[redacted]	[redacted]	[redacted]	[redacted]
●	[redacted]	[redacted]	[redacted]
[redacted]			
[redacted]	[redacted]	[redacted]	[redacted]

HEPARIN SODIUM

INJECTABLE; INJECTION

> ADD > HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%
> ADD > ● ABBOTT 10,000 UNITS/100ML N18911 006 JAN 30, 1985
> ADD > [redacted]
> DLT > [redacted]
> DLT > AP [redacted]
> DLT > [redacted]
> ADD > ● 5,000 UNITS/100ML N18911 007 JAN 30, 1985
> ADD > HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
> DLT > AP [redacted]
> DLT > 5,000 UNITS/100ML N19339 001 MAR 27, 1985
> ADD > HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
> ADD > ● B BRAUN 5,000 UNITS/100ML N19802 001 JUL 20, 1992
● [redacted]
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
● B BRAUN 200 UNITS/100ML N19042 002 MAR 29, 1985
● [redacted]
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 4,000 UNITS/100ML N19952 001 JUL 20, 1992
AP [redacted]
> DLT > [redacted]
> DLT > AP [redacted]
> DLT > [redacted]
> DLT > AP [redacted]
> DLT > [redacted]
> ADD > ● 5,000 UNITS/100ML N18911 009 JAN 30, 1985
> ADD > ● 10,000 UNITS/100ML N18911 008 JAN 30, 1985
> ADD > HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 5,000 UNITS/100ML N19952 004 JUL 20, 1992

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN 10,000 UNITS/100ML N19952 005 JUL 20, 1992
● 5,000 UNITS/100ML N19134 001
AP [redacted]
AP [redacted]
● [redacted]

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
● B BRAUN 5,000 UNITS/100ML N19802 005 JUL 20, 1992
● 10,000 UNITS/100ML N19802 002 JUL 20, 1992
● [redacted]
● [redacted]

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
● B BRAUN 5,000 UNITS/100ML N19135 001 MAR 29, 1985
● 5,000 UNITS/100ML N19802 003 JUL 20, 1992
● [redacted]
● [redacted]

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
● B BRAUN 1,000 UNITS/100ML N19042 004 MAR 29, 1985
● [redacted]

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
AVAPRO HCT
● SANOFI 12.5MG;75MG N20758 001 SEP 30, 1997

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
AVAPRO HCT
+ SANOFI 12.5MG;150MG N20758 002 SEP 30, 1997

[redacted]

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE
[redacted]

● 15MG;250MG N70829 001 MAR 09, 1987

● 25MG;250MG N70830 001 MAR 09, 1987

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
>ADD> AB GENEVA PHARMS 25MG;25MG N86881 001
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
>DLT> [redacted]

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
AB BARR 25MG;37.5MG N74970 001 JAN 06, 1998

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
AB BARR 25MG;37.5MG N71251 002 MAY 05, 1998

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL
DIOVAN HCT
NOVARTIS 12.5MG;80MG N20818 001 MAR 06, 1998
+ 12.5MG;160MG N20818 002 MAR 06, 1998

HYDROCORTISONE

CREAM; TOPICAL
ANUSOL HC
[redacted]
AT PARKEDALE 2.5% M88250 001 JUN 06, 1984

SOLUTION; TOPICAL
TEXACORT
[redacted]
AT + MEDICIS 1% M80425 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC
CORTISPORIN
[redacted]
AT + MONARCH PHARMS 1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML M60613 001

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
PAREMYD
+ AKORN 1%;0.25% N19261 001 JAN 30, 1992
[redacted]

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB		MYLAN	200MG	N40274 001 MAY 29, 1998
		HYDROXYCHLOROQUINE SULFATE		
[illegible]		[illegible]	[illegible]	[illegible]
AB		WATSON LABS	200MG	N40133 001 NOV 30, 1995

HYDROXYUREA

CAPSULE; ORAL

DROXIA

		BRISTOL MYERS SQUIBB	200MG	[illegible]
			200MG	N16295 002 FEB 25, 1998
			300MG	N16295 003 FEB 25, 1998
	+		400MG	N16295 004 FEB 25, 1998

HYDREA

AB	+	BRISTOL MYERS SQUIBB	500MG	N16295 001
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HCL

[illegible]		[illegible]	[illegible]	[illegible]
[illegible]			[illegible]	[illegible]
[illegible]			[illegible]	[illegible]
AB		WATSON LABS	10MG	[illegible] MAR 18, 1994
AB			25MG	N81150 001 MAR 18, 1994
AB			50MG	N81151 001 MAR 18, 1994

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ADVIL

[illegible]		[illegible]	[illegible]	[illegible]
BX		WHITEHALL ROBINS	100MG/5ML	N19833 002 SEP 19, 1989

IBUPROFEN

AB		ALPHARMA	100MG/5ML	N74978 001 MAR 25, 1998

MOTRIN

AB	+	MCNEIL	100MG/5ML	N19842 001 SEP 19, 1989
[illegible]	[illegible]		[illegible]	[illegible]

TABLET; ORAL

IBUPROFEN

AB		INVAMED	[illegible]	[illegible]
[illegible]			[illegible]	[illegible]
[illegible]			[illegible]	[illegible]
	@		400MG	N72064 001 JAN 14, 1988
	@		600MG	N72065 001 JAN 14, 1988
	@		800MG	N71938 001 JAN 14, 1988

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

AB		TEVA	1.25MG	N74498 002 FEB 12, 1998

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB		EON	75MG	N74464 001 MAY 28, 1998

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

AP	ELKINS SINN	51%	N74629 004 MAR 31, 1998

IOPAMIDOL-250

AP	ABBOTT	51%	N75005 001 FEB 24, 1998

IOPAMIDOL-300

AP	ABBOTT	61%	N75005 002 FEB 24, 1998

IOPAMIDOL-370

AP	ABBOTT	76%	N75005 003 FEB 24, 1998

IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST 190

[redacted]	[redacted]	[redacted]
BERLEX LABS	40.6%	N19580 001 DEC 07, 1989

OSMOVIST 240

[redacted]	[redacted]	[redacted]
BERLEX LABS	51.3%	N19580 002 DEC 07, 1989

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

+	MALLINCKRODT	51%	N20923 001 MAY 28, 1998

OPTIRAY 320

+	MALLINCKRODT	68%	N20923 002 MAY 29, 1998

OPTIRAY 350

+	MALLINCKRODT	74%	N20923 003 MAY 28, 1998

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

[redacted]	[redacted]	[redacted]	[redacted]
+		0.018MG/INH	N19085 001 DEC 29, 1986

ISOSULFAN BLUE

INJECTABLE; INJECTION

LYMPHAZURIN

[redacted]	[redacted]	[redacted]	[redacted]
+	US SURGCL	1%	N18310 001

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AP	+	PARKEDALE	EQ 50MG BASE/ML	N16812 002
AP	+		EQ 100MG BASE/ML	N16812 003
	+		EQ 10MG BASE/ML	N16812 001

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

ORUVAIL

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
		100MG	N19816 003 FEB 08, 1995
		150MG	N19816 002 FEB 08, 1995

LEPIRUDIN

INJECTABLE; INJECTION

REFLUDAN

+	HOECHST MARION RSSL	50MG/VIAL	N20807 001 MAR 06, 1998

LIDOCAINE

DISC; ORAL
XYLOCAINE
> DLT > [redacted] [redacted] [redacted]
> ADD > + 10% N14394 001

LIDOCAINE; PRILOCAINE

DISC; TOPICAL
EMLA
+ ASTRA 2.5%;2.5% N20962 001
FEB 04, 1998

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL
> ADD > AP AM PHARM PARTNERS 2% N17584 001
> ADD > AP 4% N17584 002
> DLT > [redacted] [redacted] [redacted]
> DLT > [redacted] [redacted] [redacted]

LISINOPRIL

TABLET; ORAL
ZESTRIL
> DLT > [redacted] [redacted] [redacted]
> DLT >
> ADD > AB 2.5MG N19777 005
> ADD > APR 29, 1993
> DLT > [redacted] [redacted] [redacted]
> DLT >
> ADD > AB + 10MG N19777 002
> ADD > MAY 19, 1988

LORATADINE

[redacted]
[redacted]
[redacted] [redacted] [redacted]

TABLET, ORALLY DISINTEGRATING; ORAL
CLARITIN REDITABS
+ SCHERING 10MG N20704 001
DEC 23, 1996

LORAZEPAM

TABLET; ORAL
LORAZEPAM
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted]
[redacted] [redacted]
AB WATSON LABS 0.5MG OCT 31, 1991
AB 1MG N72927 001
OCT 31, 1991
AB 2MG N72928 001
OCT 31, 1991

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
ALREX
+ PHARMOS 0.2% N20803 001
MAR 09, 1998

LOTEMAX
+ PHARMOS 0.5% N20583 001
MAR 09, 1998
+ 0.5% N20841 001
MAR 09, 1998

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL
LOXITANE C
[redacted] [redacted] [redacted]
+ WATSON LABS EQ 25MG BASE/ML N17658 001

INJECTABLE; INJECTION
LOXITANE IM
[redacted] [redacted] [redacted]
+ WATSON LABS EQ 50MG BASE/ML N18039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXITANE
[redacted] [redacted] [redacted]

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXITANE
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]
AB WATSON LABS [redacted] N17525 001
AB [redacted] [redacted] N17525 002
AB + [redacted] [redacted] N17525 003
AB [redacted] [redacted] N17525 004

TABLET; ORAL
LOXITANE
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]
@ WATSON LABS EQ 10MG BASE N17525 006
@ EQ 25MG BASE N17525 007
@ EQ 50MG BASE N17525 008

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON
+ BERTEK PHARMS EQ 85MG BASE/GM N16763 001
[redacted] [redacted] [redacted] [redacted]

> ADD > POWDER FOR RECONSTITUTION; TOPICAL
> ADD > SULFAMYLON
> ADD > + MYLAN 5% N19832 003
> ADD > JUN 05, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER
B BRAUN 30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML N19696 001
SEP 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER
[redacted] [redacted] [redacted]
[redacted] [redacted] [redacted]

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN PLASTIC CONTAINER
AP B BRAUN 30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N18252 001
AP 30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N19711 001
SEP 29, 1989
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]

MALATHION

LOTION; TOPICAL
OVIDE
[redacted] [redacted] [redacted] [redacted]
@ MEDICIS 0.5% N18613 001
AUG 02, 1982

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10% IN PLASTIC CONTAINER
AP B BRAUN 10GM/100ML N20006 002
JUL 26, 1993
[redacted] [redacted] [redacted] [redacted]
MANNITOL 15% IN PLASTIC CONTAINER
AP B BRAUN 15GM/100ML N20006 003
JUL 26, 1993

MANNITOL

INJECTABLE; INJECTION
MANNITOL 15% IN PLASTIC CONTAINER
[redacted] [redacted] [redacted] [redacted]

MANNITOL 20%
AP B BRAUN 20GM/100ML N14738 001
[redacted] [redacted] [redacted] [redacted]
MANNITOL 20% IN PLASTIC CONTAINER
AP B BRAUN 20GM/100ML N20006 004 JUL 26, 1993
[redacted] [redacted] [redacted] [redacted]
MANNITOL 5% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML N20006 001 JUL 26, 1993
[redacted] [redacted] [redacted] [redacted]

SOLUTION; IRRIGATION
RESECTISOL IN PLASTIC CONTAINER
B BRAUN 5GM/100ML N16772 002
[redacted] [redacted] [redacted]

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL
INVERSINE
+ LAYTON 2.5MG N10251 001
[redacted] [redacted] [redacted] [redacted]

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE
AB PHARMACHEMIE 40MG N74745 001 FEB 27, 1998

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL
[redacted] [redacted] [redacted] [redacted]

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL
AA WATSON LABS 50MG N40186 001 JUN 30, 1997

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/50M-21
[redacted] [redacted] [redacted] [redacted]
AB SEARLE 0.05MG;1MG N71539 001 APR 12, 1988

TABLET; ORAL-28
NORETHIN 1/50M-28
[redacted] [redacted] [redacted] [redacted]
AB SEARLE 0.05MG;1MG N71540 001 APR 12, 1988

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL
METHADONE HCL
AA ROXANE 10MG/ML N40180 001 APR 30, 1998

TABLET; ORAL
METHADONE HCL
AA EON 5MG N40241 001 MAY 29, 1998
AA 10MG N40241 002 MAY 29, 1998

TABLET, DISPERSIBLE; ORAL
METHADONE HCL
AA EON 40MG N75082 001 MAR 25, 1998

METHOCARBAMOL

INJECTABLE; INJECTION

[redacted]			
●		100MG/ML	N89849 001 DEC 27, 1991

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL

[redacted]			
[redacted]			
●		EQ 5MG BASE	N72436 001 JUN 22, 1989
●		EQ 10MG BASE	N70850 001 FEB 03, 1987

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	DANBURY PHARMA	150MG	N74865 001 APR 13, 1998
AB		200MG	N74865 002 APR 13, 1998
AB		250MG	N74865 003 APR 13, 1998

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	SUPERGEN	5MG/VIAL	N64144 001 APR 30, 1998
AP		20MG/VIAL	N64144 002 APR 30, 1998

MONTELUKAST SODIUM

TABLET; ORAL
SINGULAR

+	MERCK	EQ 10MG BASE	N20829 002 FEB 20, 1998

TABLET, CHEWABLE; ORAL
SINGULAIR

+	MERCK	EQ 5MG BASE	N20830 001 FEB 20, 1998

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL

AP	KING PHARMS	10MG/ML	N74471 001 MAR 19, 1998
AP		20MG/ML	N74471 002 MAR 19, 1998

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

[redacted]			
●		0.4MG/ML	N70172 001 SEP 24, 1986

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES

[redacted]			
AB	WATSON LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL

AB	BARR	50MG		N74918 001 MAY 08, 1998
	REVIA			
AB	+ DUPONT MERCK	50MG		N18932 001 NOV 20, 1984

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
EC-NAPROSYN

AB	+ SYNTEX	375MG		N20067 002 OCT 14, 1994
AB	+	500MG		N20067 003 OCT 14, 1994
	NAPROXEN			
AB	INVAMED	375MG		N75061 001 FEB 18, 1998
AB		500MG		N75061 002 FEB 18, 1998
AB	PUREPAC PHARM	375MG		N74936 001 FEB 24, 1998
AB		500MG		N74936 002 FEB 24, 1998
>ADD> AB	TEVA	375MG		N75227 001 JUN 30, 1998
>ADD> AB		500MG		N75227 002 JUN 30, 1998

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB	AL HIKMA	EQ 250MG BASE		N74480 002 FEB 18, 1998

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
AMERGE

	GLAXO WELLCOME	EQ 1MG BASE		N20763 002 FEB 10, 1998

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
AMERGE

+	GLAXO WELLCOME	EQ 2.5MG BASE		N20763 001 FEB 10, 1998

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

[redacted]		[redacted]		[redacted]
+		EQ 350MG BASE		N60304 001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION
NEOSPORIN G.U. IRRIGANT

[redacted]	[redacted]	[redacted]		[redacted]
AT	MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML		N60707 001

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL
TPN SUSPENSION

+	INTL MINERALS	15MG/5ML;3.75MG/5ML; 600MG/5ML		N08378 003

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL
NICARDIPINE HCL

AB	GEMPHARM	20MG		N74928 001 MAR 19, 1998
AB		30MG		N74928 002 MAR 19, 1998

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
MINITRAN

[redacted]	[redacted]	[redacted]		[redacted]

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

AB1	3M	0.1MG/HR	N89771 001	AUG 30, 1996
AB		0.2MG/HR	N89772 001	AUG 30, 1996
AB1		0.2MG/HR	N89772 001	AUG 30, 1996
AB		0.4MG/HR	N89773 001	AUG 30, 1996
AB1		0.4MG/HR	N89773 001	AUG 30, 1996
AB		0.6MG/HR	N89774 001	AUG 30, 1996
AB1		0.6MG/HR	N89774 001	AUG 30, 1996

NITRO-DUR

AB	* KEY PHARMS	0.1MG/HR	N20145 001	APR 04, 1995
AB1	+	0.1MG/HR	N20145 001	APR 04, 1995
AB	*	0.2MG/HR	N20145 002	APR 04, 1995
AB1	+	0.2MG/HR	N20145 002	APR 04, 1995
AB	*	0.4MG/HR	N20145 004	APR 04, 1995
AB1	+	0.4MG/HR	N20145 004	APR 04, 1995
AB	*	0.6MG/HR	N20145 005	APR 04, 1995
AB1	+	0.6MG/HR	N20145 005	APR 04, 1995

NITROGLYCERIN

AB2	MYLAN	0.1MG/HR	M75033 001	FEB 06, 1998
AB		0.2MG/HR	M74609 001	AUG 30, 1996
AB2		0.2MG/HR	M74609 001	AUG 30, 1996
AB		0.4MG/HR	M74607 001	AUG 30, 1996
AB2		0.4MG/HR	M74607 001	AUG 30, 1996

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

AB2	MYLAN	0.6MG/HR	N74559 001	AUG 30, 1996

TRANSDERM-NITRO

AB2	+ NOVARTIS	0.1MG/HR	N20144 001	FEB 27, 1996
AB	*	0.2MG/HR	N20144 002	FEB 27, 1996
AB2	+	0.2MG/HR	N20144 002	FEB 27, 1996
AB	*	0.4MG/HR	N20144 003	FEB 27, 1996
AB2	+	0.4MG/HR	N20144 003	FEB 27, 1996
AB	*	0.6MG/HR	N20144 004	FEB 27, 1996
AB2	+	0.6MG/HR	N20144 004	FEB 27, 1996
RX	*	0.1MG/HR	N20144 001	FEB 27, 1996

NORETHINDRONE

TABLET; ORAL

NOR-QD

*	BRANLR	0.35MG	N17060 001
+	WATSON LABS	0.35MG	N17060 001

NYSTATIN

SUSPENSION; ORAL

NYSTATIN

AA	UDL	100,000 UNITS/ML	M64142 001	JUN 25, 1998

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PRILOSEC

+	ASTRA MERCK	40MG	N19810 002	JAN 15, 1998

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

> ADD > AB + 3M 100MG N12157 001

> ADD > ORPHENADRINE CITRATE

> ADD > AB INVAMED 100MG N40284 001

> ADD > JUN 19, 1998

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

DITROPAN

AA + ALZA 5MG/5ML N18211 001

AA * [redacted] [redacted] [redacted]

TABLET; ORAL

DITROPAN

AB + ALZA 5MG N17577 001

AB * [redacted] [redacted] [redacted]

OXYTOCIN

INJECTABLE; INJECTION

PITOCIN

AP * [redacted] [redacted] [redacted]

AP + PARKEDALE 10 USP UNITS/ML N18261 001

PARICALCITOL

INJECTABLE; INJECTION

ZEMPLAR

+ ABBOTT 0.005MG/ML N20819 001

APR 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

AB * [redacted] [redacted] [redacted] [redacted]

AB [redacted] [redacted] [redacted]

AB + PARKEDALE EQ 250MG BASE N60521 001

AB EQ 250MG BASE N62310 001

PAROMOMYCIN SULFATE

> ADD > AA CARACO EQ 250MG BASE N64171 001

> ADD > JUN 30, 1997

> DLT > AA [redacted] [redacted] [redacted] [redacted]

> DLT [redacted]

PAROMOMYCIN SULFATE

CAPSULE; ORAL

PAROMOMYCIN SULFATE

AA [redacted] [redacted] [redacted] [redacted]

[redacted]

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ ALZA 100MG N20193 001

SEP 26, 1996

* [redacted] [redacted] [redacted] [redacted]

[redacted]

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB + ALLERGAN 5% N19855 001

AUG 25, 1989

PERMETHRIN

AB ALPHARMA 5% N74806 001

JAN 23, 1998

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

AZO GANTRISIN

* ROCHE 50MG;500MG [redacted] [redacted]

[redacted]

@ 50MG;500MG N19358 001

AUG 31, 1990

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HCL

AA [redacted] [redacted] [redacted] [redacted]

[redacted]

@ 37.5MG N88414 001

OCT 19, 1983

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL
PHENTERMINE HCL

[redacted]		[redacted]	[redacted]
●		30MG	N88605 001 SEP 28, 1987

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION
PHENTOLAMINE MESYLATE

AP	BEDFORD	5MG/VIAL	N40235 001 MAR 11, 1998

REGITINE

AP	+ NOVARTIS	5MG/VIAL	N08278 003

PINDOLOL

TABLET; ORAL
PINDOLOL

[redacted]		[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
●		5MG	N74125 001 APR 28, 1993
●		10MG	N74125 002 APR 28, 1993
[redacted]		[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
AB	WATSON LABS	5MG	N74437 001 FEB 27, 1995
AB		10MG	N74437 002 FEB 27, 1995

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
ZOSYN IN PLASTIC CONTAINER

+	LEDERLE	EQ 40MG BASE/ML; EQ 5MG BASE/ML	N50750 001 FEB 24, 1998

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
ZOSYN IN PLASTIC CONTAINER

+	LEDERLE	EQ 4GM BASE/100ML; EQ 500MG BASE/100ML	N50750 003 FEB 24, 1998
+		EQ 60MG BASE/ML; EQ 7.5MG BASE/ML	N50750 002 FEB 24, 1998

PIROXICAM

CAPSULE; ORAL
PIROXICAM

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
AB	WATSON LABS	10MG	N74460 001 SEP 29, 1995
AB		20MG	N74460 002 SEP 29, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
[redacted]

AB	[redacted]	[redacted]	[redacted]
●		236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001 AUG 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
[redacted]

[redacted]	[redacted]	[redacted]	[redacted]
●		EQ 500,000 U BASE/VIAL	N62036 001

POLYMYXIN B SULFATE

[redacted]	[redacted]	[redacted]	[redacted]
AP	+	EQ 500,000 U BASE/VIAL	N60716 001

POLYMYXIN B SULFATE

POWDER; FOR RX COMPOUNDING

	POLY-RX			
AA	[redacted]	[redacted]	[redacted]	
	+			
	[redacted]			
AA	[redacted]	[redacted]	[redacted]	
	●		100,000,000 UNITS/BOT	N62455 001 JUL 27, 1983

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE			
AT	ALCON	10,000 UNITS/ML; EQ 1MG BASE/ML		N64211 001 APR 13, 1998

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE			
AP	B BRAUN	2MEQ/ML		N85870 001
AP	[redacted]	[redacted]	[redacted]	[redacted]

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

● B BRAUN	75MG/100ML;900MG/100ML		N18722 001 NOV 09, 1982
● [redacted]	[redacted]	[redacted]	[redacted]

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

● B BRAUN	150MG/100ML;900MG/100ML		N18722 002 NOV 09, 1982
● [redacted]	[redacted]	[redacted]	[redacted]

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

● B BRAUN	220MG/100ML;900MG/100ML		N18722 003 NOV 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

● [redacted]	[redacted]	[redacted]	[redacted]

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

● B BRAUN	300MG/100ML;900MG/100ML		N18722 004 NOV 09, 1982
● [redacted]	[redacted]	[redacted]	[redacted]

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

	MIRAPEX			
	PHARMACIA AND UPJOHN	0.5MG		N20667 006 FEB 12, 1998

PREDNISOLONE

SYRUP; ORAL

	PRE-PRED			
AA	WE PHARMS	15MG/5ML		N40192 001 MAY 28, 1998
	PRELONE			
AA	+ MURO	15MG/5ML		N89081 001 FEB 04, 1986

TABLET; ORAL

	PREDNISOLONE			
RX	[redacted]	5MG		[redacted]
RX	+	5MG		N80354 001
RX	[redacted]	[redacted]	[redacted]	[redacted]
	●	5MG		N80339 001

PRIMIDONE

SUSPENSION; ORAL

	MYSOLINE			
	+ ELAN PHARMA	250MG/5ML		N10401 001
	[redacted]	[redacted]	[redacted]	[redacted]

TABLET; ORAL

	MYSOLINE			
AB	+ ELAN PHARMA	250MG		N09170 002

PRIMIDONE

TABLET; ORAL
MYSOLINE

	+	ELAN PHARMA	50MG	N09170 003
[redacted]		[redacted]	[redacted]	[redacted]

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL

[redacted]		[redacted]	[redacted]	[redacted]
	●		500MG	N89284 001 JUN 23, 1988
[redacted]		[redacted]	[redacted]	[redacted]
	●		250MG	N88958 001 DEC 02, 1985

PROCAN SR

[redacted]		[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]
AB	*		1GM	N88489 001 JAN 16, 1985
AB	+	PARKEDALE	500MG	N86065 001
AB	+		750MG	N87510 001 APR 01, 1982
AB	+		1GM	N88489 001 JAN 16, 1985

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

[redacted]		[redacted]	[redacted]	[redacted]
	●		EQ 5MG BASE/ML	N89675 001 DEC 05, 1988

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB		TRIGEN	EQ 5MG BASE	N40268 001 FEB 27, 1998

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB		TRIGEN	EQ 10MG BASE	N40268 002 FEB 27, 1998
AB		ZENITH GOLDLINE	EQ 5MG BASE	N40162 001 JAN 20, 1998
AB			EQ 10MG BASE	N40162 002 JAN 20, 1998

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM

	+	SCHERING PLOUGH	100MG	N19781 001 MAY 14, 1998

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP		[redacted]	[redacted]	[redacted]
AP			[redacted]	[redacted]
	●		25MG/ML	N89463 001 MAY 02, 1988
	●		50MG/ML	N89477 001 MAY 02, 1988

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

[redacted]		[redacted]	[redacted]	[redacted]
	●		65MG	N83278 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

[redacted]		[redacted]	[redacted]	[redacted]

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	[illegible]	[illegible]	[illegible]				
AB		[illegible]					
AB		[illegible]					
AB		[illegible]					
AB		[illegible]					
	●	10MG	N71658 001 JUL 05, 1988	> ADD >			
	●	20MG	N71687 001 JUL 05, 1988	> ADD >			
	●	40MG	N71688 001 JUL 05, 1988				
	●	60MG	N72197 001 JUL 05, 1988	> ADD >			
	●	80MG	N71689 001 JUL 05, 1988	> ADD >			
	●	90MG	N72198 001 JUL 05, 1988	> ADD >			

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

AB	[illegible]	[illegible]	[illegible]				
	●	200MG	N84003 001				

TABLET, EXTENDED RELEASE; ORAL
QUINIDEX

> ADD >	AB	+ ROBINS AH	300MG	N12796 002	> ADD >		
> DLT >	AB	# [illegible]	[illegible]	[illegible]	> ADD >		

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL
ZANTAC

	[illegible]	[illegible]	[illegible]	> ADD >			
	+	EQ 15MG BASE/ML	N19675 001 DEC 30, 1988	> ADD >			

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

AB	RANBAXY	EQ 150MG BASE	N75000 001 JAN 30, 1998				
AB		EQ 300MG BASE	N75000 002 JAN 30, 1998				

RIFAMPIN

CAPSULE; ORAL
RIFADIN

AB	HOECHST MARION RSSL	150MG	N62303 001				

RIFAMPIN

AB	EON	150MG	N64150 002 JAN 02, 1998				

RIFAPENTINE

TABLET; ORAL
PRIFTIN

	+ HOECHST MARION RSSL	150MG	N21024 001 JUN 22, 1998				

RISEDRONATE SODIUM

TABLET; ORAL
ACTONEL

	+ PROCTER AND GAMBLE	30MG	N20835 001 MAR 27, 1998				

RIZATRIPTAN BENZOATE

TABLET; ORAL
MAXALT

	MERCK	EQ 5MG BASE	N20864 001 JUN 29, 1998				
	+	EQ 10MG BASE	N20864 002 JUN 29, 1998				

TABLET, ORALLY DISINTEGRATING; ORAL
MAXALT-MLT

	MERCK	EQ 5MG BASE	N20865 001 JUN 29, 1998				

>ADD> **RIZATRIPTAN BENZOATE**

>ADD> TABLET, ORALLY DISINTEGRATING; ORAL
>ADD> MAXALT-MLT
>ADD> + MERCK — EQ 10MG BASE — N20865 002 JUN 29, 1998
>ADD>

SACROSIDASE

SOLUTION; ORAL
SUCRAID
+ ORPHAN MEDCL — 8,500 IU/ML — N20772 001 APR 09, 1998

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE
[redacted] — [redacted] — [redacted]
+ — 200MG — N20828 001 NOV 07, 1997

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HCL
AB ESI LEDERLE — 5MG — N74641 001 AUG 02, 1996
[redacted] — [redacted] — [redacted]
AB STASON — 5MG — N74912 001 APR 30, 1998

SILDENAFIL CITRATE

TABLET; ORAL
VIAGRA
PFIZER — 25MG — N20895 001 MAR 27, 1998
50MG — N20895 002 MAR 27, 1998
+ — 100MG — N20895 003 MAR 27, 1998

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN — 450MG/100ML — N19635 001 MAR 09, 1988
@ — 450MG/100ML — N18184 001
[redacted] — [redacted] — [redacted]
— 450MG/100ML — [redacted]
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN — 900MG/100ML — N17464 001
AP — 900MG/100ML — N19635 002 MAR 09, 1988
[redacted] — [redacted] — [redacted]
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER
@ B BRAUN — 3GM/100ML — N19635 003 MAR 09, 1988
[redacted] — [redacted] — [redacted]
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER
@ B BRAUN — 5GM/100ML — N19635 004 MAR 09, 1988
[redacted] — [redacted] — [redacted]

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER
@ B BRAUN — 1.87GM/100ML — N18186 001
[redacted] — [redacted] — [redacted]
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER
AP B BRAUN — 1.87GM/100ML — N20004 001 APR 21, 1992
[redacted] — [redacted] — [redacted]

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
KAYEXALATE
[redacted] — [redacted] — [redacted]
AA + — 453.6GM/BOT — N11287 001

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

	KIONEX				
AA	PADDOCK	454GM/BOT	N40029 001 FEB 06, 1998		

SOTALOL HYDROCHLORIDE

TABLET; ORAL

	BETAPACE				
	[redacted]	120MG	[redacted]		
		160MG			
	[redacted]	240MG			
		120MG	N19865 005 APR 20, 1994		
+		160MG	N19865 002 OCT 30, 1992		
		240MG	N19865 003 OCT 30, 1992	> ADD > > ADD >	

SOYBEAN OIL

INJECTABLE; INJECTION

	INTRALIPID 30%				
AP	+ PHARMACIA AND UPJOHN	30%	N19942 001 DEC 30, 1993		
	LIPOSYN III 30%				
AP	+ ABBOTT	30%	N20181 001 JAN 13, 1998		
	NUTRILIPID 10%				
AP	+ B BRAUN	10%	N19531 001 MAY 28, 1993		
AP	+ [redacted]	10%	[redacted]		
	NUTRILIPID 20%				
AP	+ B BRAUN	20%	N19531 002 MAY 28, 1993	> DLT > > DLT > > ADD >	
AP	+ [redacted]	20%	[redacted]		

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

	STREPTOMYCIN SULFATE				
AP	+ PFIZER	EQ 1GM BASE/VIAL	N60076 001		
		[redacted]	[redacted]		
	+	EQ 1GM BASE/2.5ML	N60111 001		
	> ADD >				
AP	PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001 JUN 30, 1998		
	> ADD >				

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

	SUCOSTRIN				
AP	+ [redacted]	20MG/ML	[redacted]		
	@	20MG/ML	N08847 001		

SUCRALFATE

TABLET; ORAL

	SUCRALFATE				
AB	RATIOPHARM	1GM	N74415 001 JUN 08, 1998	> ADD > > ADD >	

SUFENTANIL CITRATE

INJECTABLE; INJECTION

	SUFENTA				
AP	+ AKORN	EQ 0.05MG BASE/ML	N19050 001 MAY 04, 1984		
AP	+ JANSSEN	EQ 0.05MG BASE/ML	[redacted]		

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

	SULF-10				
AT	CIBA	10%	[redacted]		
	@	10%	N80025 001		

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

AB	[redacted] TEVA	[redacted]	[redacted]	N18812 001 JAN 28, 1983	
AB	[redacted] TEVA	[redacted]	[redacted]	N18812 002 JUN 10, 1983	
	SULFAMETHOXAZOLE AND TRIMETHOPRIM				
AB	TEVA	200MG/5ML;40MG/5ML		N18812 001 JAN 28, 1983	
AB		200MG/5ML;40MG/5ML		N18812 002 JUN 10, 1983	

TABLET; ORAL

	[redacted]				> DLT >
AB	TEVA	[redacted]		[redacted]	> DLT >
AB	[redacted]	[redacted]		[redacted]	> DLT >
	SULFAMETHOXAZOLE AND TRIMETHOPRIM				> DLT >
AB	TEVA	400MG;80MG		N18242 001	> ADD >
AB		800MG;160MG		N18242 002	> ADD >
					> ADD >
					> ADD >

SULFASALAZINE

TABLET; ORAL

	SULFASALAZINE				> DLT >
AB	SUPERPHARM	500MG		[redacted] OCT 26, 1987	> DLT >
	@	500MG		N89339 001 OCT 26, 1987	> ADD >

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

	PARKE DAVIS	EQ 10MG BASE		N20070 001 SEP 09, 1993
		EQ 20MG BASE		N20070 002 SEP 09, 1993
		EQ 30MG BASE		N20070 003 SEP 09, 1993
*		EQ 40MG BASE		N20070 004 SEP 09, 1993
	PARKE DAVIS PHARMS	EQ 10MG BASE		N20070 001 SEP 09, 1993
		EQ 20MG BASE		N20070 002 SEP 09, 1993
		EQ 30MG BASE		N20070 003 SEP 09, 1993
+		EQ 40MG BASE		N20070 004 SEP 09, 1993

TACROLIMUS

CAPSULE; ORAL

PROGRAF

*	[redacted]	[redacted]		[redacted] APR 08, 1994
*		[redacted]		[redacted] APR 08, 1994
+	FUJISAWA HLTHCARE	EQ 1MG BASE		N50708 001 APR 08, 1994
+		EQ 5MG BASE		N50708 002 APR 08, 1994

INJECTABLE; INJECTION

PROGRAF

*	[redacted]	[redacted]		[redacted] APR 08, 1994
+	FUJISAWA HLTHCARE	EQ 5MG BASE/ML		N50709 001 APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

BS	DRAXIMAGE	N/A		N17881 001 DEC 30, 1987
BS	[redacted]	[redacted]		[redacted] DEC 30, 1987

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION

HEPATOLITE

	[redacted]	[redacted]		[redacted] MAR 15, 1982

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE

	DUPONT MERCK		N/A	N18467 001 MAR 16, 1982

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
TECHNESCAN GLUCEPTATE

AP	DRAXIMAGE		N/A	N18272 001 JAN 27, 1982
AP	MERCK SHARP DOHME		N/A	N18272 001 JAN 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
TECHNESCAN HIDA

	DRAXIMAGE		N/A	N18489 001 OCT 31, 1986
	MERCK		N/A	N18489 001 OCT 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
TECHNESCAN MDP KIT

AP	DRAXIMAGE		N/A	N18035 001
AP	MERCK SHARP DOHME		N/A	N18035 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
DTPA

AP	DRAXIMAGE		N/A	N18511 001 DEC 29, 1989
AP	MERCK		N/A	N18511 001 DEC 29, 1989

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
SULFUR COLLOID

AP	CIS		N/A	N17858 001
	◎		N/A	N17858 001

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
HYTRIN

AB	ABBOTT		EQ 1MG BASE	N20347 001 DEC 14, 1994
AB	+		EQ 2MG BASE	N20347 002 DEC 14, 1994
AB			EQ 5MG BASE	N20347 003 DEC 14, 1994
AB			EQ 10MG BASE	N20347 004 DEC 14, 1994

TERAZOSIN HCL

AB	GENEVA PHARMS		EQ 1MG BASE	N74823 001 MAR 30, 1998
AB			EQ 2MG BASE	N74823 002 MAR 30, 1998
AB			EQ 5MG BASE	N74823 003 MAR 30, 1998
AB			EQ 10MG BASE	N74823 004 MAR 30, 1998

TERBINAFINE

GEL; TOPICAL
LAMISIL

	+	NOVARTIS	1%	N20846 001 APR 29, 1998

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

RX	+	TRIMARCH	2.5MG/24HR	N20489 001 SEP 29, 1995
	+		2.5MG/24HR	N20489 001 SEP 29, 1995

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
ACHROMYCIN V

>ADD>	AB		ESI LEDERLE	250MG	N50278 003
>ADD>	AB	+		500MG	N50278 001
>DLT>	[redacted]		[redacted]	[redacted]	[redacted]
>DLT>	[redacted]	[redacted]		[redacted]	[redacted]

THEOPHYLLINE

[redacted]

[redacted]		[redacted]	[redacted]	[redacted]
[redacted]	[redacted]		[redacted]	[redacted]
	●		100MG	N85545 001 JUL 31, 1984
	●		200MG	N83921 001 JUL 31, 1984

CAPSULE, EXTENDED RELEASE; ORAL
[redacted]

[redacted]		[redacted]	[redacted]	[redacted]
[redacted]			[redacted]	[redacted]
	●		125MG	N86826 001 JAN 29, 1985
	●		250MG	N86826 002 JAN 29, 1985

TABLET; ORAL
QUIBRON-T

	+	MONARCH PHARMS	300MG	N88656 001 AUG 22, 1985
	[redacted]	[redacted]	[redacted]	[redacted]

TABLET, EXTENDED RELEASE; ORAL
QUIBRON-T/SR

[redacted]	[redacted]	[redacted]	[redacted]
BC	MONARCH PHARMS	300MG	N87563 001 JUN 21, 1983

THIAMYLAL SODIUM

[redacted]

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
●	PARKEDALE	1GM/VIAL	N07600 003
●		5GM/VIAL	N07600 005
●		10GM/VIAL	N07600 009

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL

AA	PHARM ASSOC	100MG/ML	N40213 001 MAY 29, 1998

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION
AGGRASTAT

+	MERCK	EQ 0.05MG BASE/ML	N20913 001 MAY 14, 1998
+		EQ 0.25MG BASE/ML	N20912 001 MAY 14, 1998

TOLCAPONE

TABLET; ORAL
TASMAR

	ROCHE	100MG	N20697 001 JAN 29, 1998
+		200MG	N20697 002 JAN 29, 1998

TOLTERODINE TARTRATE

TABLET; ORAL
DETROL

	PHARMACIA AND UPJOHN	1MG	N20771 001 MAR 25, 1998
+		2MG	N20771 002 MAR 25, 1998

TORSEMIDE

INJECTABLE; INJECTION
DEMADEX
* BOEHRINGER MANNHEIM 10MG/ML — [illegible] — > ADD >
AUG 23, 1993 — > ADD >
\+ ROCHE 10MG/ML — N20137 002 AUG 23, 1993 — > ADD >

TABLET; ORAL
DEMADEX
BOEHRINGER MANNHEIM 5MG — [illegible]
10MG — [illegible]
20MG — [illegible]
* 100MG — [illegible]
ROCHE 5MG — N20136 001 AUG 23, 1993
10MG — N20136 002 AUG 23, 1993
20MG — N20136 003 AUG 23, 1993
\+ 100MG — N20136 004 AUG 23, 1993

TRETINOIN

CREAM; TOPICAL
AVITA
AB * PENEDERM 0.025% — N20404 002 JAN 14, 1997
AB 0.025% — N20404 003 JAN 14, 1997

GEL; TOPICAL
AVITA
BX PENEDERM 0.025% — N20400 001 JAN 29, 1998
0.025% — N20400 002 JAN 29, 1998

RETIN-A
* J AND J 0.025% — N17579 002
BX \+ JOHNSON AND JOHNSON 0.025% — N17579 002 — > DLT >
> DLT >

SOLUTION; TOPICAL
RETIN-A
> DLT > * J AND J 0.05% — N16921 001 — > DLT >

TRETINOIN

SOLUTION; TOPICAL
RETIN-A
AT \+ JOHNSON AND JOHNSON 0.05% — N16921 001
TRETINOIN
AT COPLEY PHARM 0.05% — N74873 001 JUN 19, 1998

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE
@ ALPHARMA 0.025% — N87797 001 JUN 07, 1982
AT [illegible] 0.025% — [illegible] JUN 07, 1982

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL
AB ZENITH GOLDLINE EQ 1MG BASE — N87612 001 NOV 19, 1982
AB EQ 2MG BASE — N87613 001 NOV 19, 1982
AB ZENITH LABS EQ 1MG BASE — [illegible] NOV 19, 1982
AB EQ 2MG BASE — [illegible] NOV 19, 1982

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL
AA CIRCA 2MG — N40184 001 FEB 06, 1998
AA 5MG — N40184 002 FEB 06, 1998

TRIMETHAPHAN CAMSYLATE

[illegible]
ARFONAD
* ROCHE 50MG/ML — N08983 001

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION
ARFONAD

>ADD>	@	ROCHE	50MG/ML	N08983 001

TROGLITAZONE

TABLET; ORAL
REZULIN

AB		PARKE DAVIS	200MG	N20720 001 JAN 29, 1997
AB			300MG	N20720 003 AUG 04, 1997
AB			400MG	N20720 002 JAN 29, 1997
AB		PARKE DAVIS PHARMS	200MG	N20720 001 JAN 29, 1997
AB			300MG	N20720 003 AUG 04, 1997
AB			400MG	N20720 002 JAN 29, 1997

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICAMIDE

AP		AKORN	1%	N88447 001 AUG 28, 1985
	@		1%	N88447 001 AUG 28, 1985

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR
FERTINEX

	+	SERONO	75 IU/AMP	N19415 002 SEP 18, 1986
	+		150 IU/AMP	N19415 003 SEP 18, 1986

METROPIN

	*	SERONO	75 IU/AMP	N19415 002 SEP 18, 1986
	*		150 IU/AMP	N19415 003 SEP 18, 1986

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HCL

AP		MARSAM	2.5MG/ML	N72233 001 FEB 26, 1993
AP			2.5MG/ML	N73485 001 SEP 27, 1993
	@		2.5MG/ML	N72233 001 FEB 26, 1993
	@		2.5MG/ML	N73485 001 SEP 27, 1993

VIDARABINE

INJECTABLE; INJECTION
VIRA-A

	@	PARKE DAVIS	EQ 187.4MG BASE/ML	N50523 001
	@	PARKEDALE	EQ 187.4MG BASE/ML	N50523 001

OINTMENT; OPHTHALMIC
VIRA-A

	*	PARKE DAVIS	3%	N50486 001
	+	PARKEDALE	3%	N50486 001

WATER FOR INJECTION, STERILE

LIQUID; N/A
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP		B BRAUN	100%	N19633 001 FEB 29, 1988
AP		MCGAW	100%	N19633 001 FEB 29, 1988

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

EXCEDRIN (MIGRAINE)			
+ BRISTOL MYERS	250MG;250MG;65MG	N20802 001	> ADD >
		JAN 14, 1998	> ADD >

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

GAVISCON			
+ HOECHST MARION RSSL	80MG;20MG	N18685 001	
		DEC 09, 1983	
	80MG;20MG	N18685 001	
		DEC 09, 1983	
+	160MG;40MG	N18685 002	
		DEC 09, 1983	
GAVISCON-2			
+ HOECHST MARION RSSL	160MG;40MG	N18685 002	
		DEC 09, 1983	

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

CHG SCRUB			
ECOLAB	4%	N19258 002	
		JUL 22, 1986	
HUNTINGTON LABS	4%	N19258 002	
		JUL 22, 1986	
CIDA-STAT			
ECOLAB	2%	N19258 001	
		JUL 22, 1986	
HUNTINGTON LABS	2%	N19258 001	
		JUL 22, 1986	

CIMETIDINE

TABLET; ORAL

CIMETIDINE			
LEK PHARM	100MG	N75122 001	> ADD >
		JUN 19, 1998	> ADD >
	200MG	N75122 002	> ADD >
		JUN 19, 1998	> ADD >
NOVOPHARM	200MG	N74961 001	> ADD >
		JUN 19, 1998	> ADD >

CIMETIDINE

TABLET; ORAL

CIMETIDINE			
PERRIGO	100MG	N74972 001	
		JUN 19, 1998	
PHARM FORM	200MG	N74963 001	
		JUN 19, 1998	
TORPHARM	100MG	N74948 001	
		JUN 19, 1998	

CLOTRIMAZOLE

TABLET; VAGINAL

GYNIX		
COPLEY PHARM	100MG	N73249 001
		FEB 13, 1998

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ADVIL-FLAVORED		
+ WHITEHALL ROBINS	100MG/5ML	N20589 002
		NOV 07, 1997
	100MG/5ML	N20589 002
		NOV 07, 1997

SUSPENSION/DROPS; ORAL

PEDIATRIC ADVIL		
+ WHITEHALL ROBINS	100MG/2.5ML	N20812 001
		JAN 30, 1998

TABLET; ORAL

IBUPRIN		
SIDMAK LABS NJ	200MG	N71773 001
		JUL 16, 1987
@	200MG	N71773 001
		JUL 16, 1987

TABLET, CHEWABLE; ORAL

JUNIOR STRENGTH MOTRIN		
MCNEIL	100MG	N20601 003
		NOV 15, 1996
+	100MG	N20601 003
		NOV 15, 1996

MICONAZOLE NITRATE

CREAM; VAGINAL
MONISTAT 3
+ ADVANCED CARE PRODS 4% N20827 001
MAR 30, 1998

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)
NU PHARM 2% N74924 001
APR 29, 1998

MINOXIDIL (FOR WOMEN)
NU PHARM 2% N74924 002
APR 29, 1998

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NICOTROL
[redacted]

+ PHARMACIA AND UPJOHN 15MG/16HR N20536 001
JUL 03, 1996

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL
ZANTAC 75
+ GLAXO WELLCOME EQ 75MG BASE N20745 001
FEB 26, 1998

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 6 JUN '98

NO JUNE 1998 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
January 1998 through June 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Fabry's disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK, DD=05/12/1998
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Gaucher disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK, DD=05/29/1998
Aldesleukin TN= Proleukin	Treatment of metastatic melanoma.	Chiron Corporation 4560 Horton Street Emeryville, CA 94608 DD=09/10/1996 MA=01/09/1998
Aliperetinate TN= Panretin	For the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998
Alpha-galactosidase A TN=	Long-term enzyme replacement therapy for the treatment of Fabry disease.	Transkaryotic Therapies Inc. 195 Albany St. Cambridge, MA 02139 DD=06/22/1998

Orphan Product Designations and Approvals List
January 1998 through June 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Amifostine TN= Ethyol	Reduction of the incidence and severity of radiation-induced xerostomia.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998
Arsenic trioxide TN=	Treatment of acute promyelocytic leukemia.	PolaRx, Inc. 787 7th Ave., 48th Floor New York, NY 10019 DD=03/03/1998
Basiliximab TN= Simulect	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=12/12/1997 MA=05/12/1998
Beclomethasone dipropionate TN=	For oral administration in the treatment of intestinal graft-versus-host disease.	George B. McDonald, M.D. Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North (SC-113); PO Box 19024 Seattle, WA 98109 DD=03/27/1998
Benzydamine hydrochloride TN= Tantum	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=05/18/1998
Bindarit TN=	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=02/03/1998

Orphan Product Designations and Approvals List
January 1998 through June 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Carbamylglutamic acid TN=	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe Immeuble "Le Guillaumet" 60 avenue du President Wilson 92046 Paris France, DD=01/20/1998
Corticotropin-releasing factor, human TN= Xerecept	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc. 1387 Marina Way South Richmond, CA 94804 DD=04/06/1998
Dimethylsulfoxide TN=	Treatment of palmar-plantar erythrodysesthesia syndrome.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/06/1998
Filgrastim TN= Neupogen	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=11/07/1996 MA=04/02/1998
Fructose-1,6-diphosphate TN=	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=05/29/1998
Hydroxyurea TN= Droxia	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton, NJ 08543 DD=10/01/1990 MA=02/25/1998

Orphan Product Designations and Approvals List
January 1998 through June 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
L-baclofen TN=	Treatment of trigeminal neuralgia.	Pharmascience, Inc. 8400 Darnley Road Montreal, Quebec Canada H4T 1M4 DD=01/06/1998
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel Frankfurt am Main Germany DD=02/13/1997 MA=03/06/1998
Liposomal Cyclosporin A TN= Cyclospire	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D. Baylor College of Medicine, Dept. of Molecular Physiology One Baylor Plaza Houston, TX 77030 DD=04/30/1998
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl TN= ImmTher	Treatment of osteosarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl TN= ImmTher	Treatment of Ewing s sarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998

Orphan Product Designations and Approvals List
January 1998 through June 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Mafenide acetate solution TN= Sulfamylon solution	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc. 781 Chestnut Ridge Road P.O. Box 4310 Morgantown, WV 26504 DD=07/18/1990 MA=06/05/1998
Pentostatin TN=	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc. Two Annbel Lane, Suite 220 San Ramon, CA 94583 DD=03/27/1998
Phenylacetate TN=	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=03/06/1998
Pilocarpine HCl TN= Salagen	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc. 9900 Bren Road East Suite 300E Minneapolis, MN 55343 DD=02/28/1992 MA=02/11/1998
Prostaglandin E1 enol ester (AS-013) TN=	Treatment of Fontaine Stage IV chronic critical limb ischemia.	Alpha Therapeutic Corp. 5555 Valley Blvd. Los Angeles, CA 90032 DD=06/12/1998
Recombinant bactericidal/permeability-increasing protein TN= Neuprex	Treatment of severe meningococcal disease.	Xoma Corporation 2910 Seventh Street Berkeley, CA 94710 DD=06/22/1998
Recombinant humanized monclonal antibody 5c8 TN=	Treatment of immune thrombocytopenic purpura.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/03/1998

Orphan Product Designations and Approvals List
January 1998 through June 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant humanized monoclonal antibody 5c8 TN=	Treatment of systemic lupus erythematosus.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/18/1998
Rifapentine TN= Priftin	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel P.O. Box 9627 H3-M2516 Kansas City, MO 64134 DD=06/09/1995 MA=06/22/1998
Rifaximin TN= Normix	Treatment of hepatic encephalopathy.	Salix Pharmaceuticals, Inc. 3600 W. Bayshore Road Palo Alto, CA 94303 DD=02/10/1998
S-adenosylmethionine TN=	Treatment of AIDS-myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Dept. of Neurology Philips Building, Suite 2Q; 10 Union Square New York, NY 10003 DD=04/30/1998
Sacrosidase TN= Sucraid	Treatment of congenital sucrase-isomaltase deficiency.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=12/10/1993 MA=04/09/1998
Sodium phenylbutyrate TN=	For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=04/24/1998

Orphan Product Designations and Approvals List
January 1998 through June 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
TAK-603 TN=	Treatment of Crohn's disease.	TAP Holdings Inc. 2355 Waukegan Road Deerfield, IL 60015 DD=05/13/1998
Tacrolimus TN= Prograf	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=04/06/1998
Tetrabenazine TN=	Treatment for moderate/severe tardive dyskinesia.	Lifehealth Limited Richmond House, Old Brewery Court, Sandyford Road Newcastle upon Tyne NE2 1XG England DD=05/12/1998
Thalidomide TN=	Treatment of primary brain malignancies.	EntreMed, Inc. 9610 Medical Center Drive, Suite 200 Rockville, MD 20850 DD=02/27/1998
Thymalfasin TN= Zadaxin	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. San Mateo, CA 94404 DD=01/08/1998
Tiapride TN=	Treatment of Tourette's syndrome.	Synthelabo Research, Inc. 400 Plaza Drive Secaucus, NJ 07094 DD=04/21/1998
Transgenic human alpha 1 antitrypsin TN=	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K. DD=03/06/1998

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JUNE 1998 ADDITIONS

PATENT AND EXCLUSIVITY TERMS PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 18TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING *SCHEDULE*

D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM " ...1/2-1 HOUR BEFORE EATING..." TO "...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICCLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE

NEW INDICATION

I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY

PATENT USE CODE

U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKISON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGETS DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING A NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS
U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020482	004	ACARBOSE;PRECOSE	4904769	FEB 27, 2007		NCE	SEP 06, 2000
	020802	001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)				NP	JAN 14, 2001
	020059	001	ADENOSINE;ADENOSCAN	5070877	DEC 10, 2008	U-116		
				5731296	MAR 24, 2015	U-221		
>ADD>	020503	001	ALBUTEROL SULFATE;PROVENTIL-HFA	5766573	JUN 16, 2015			
>ADD>	020511	001	AMLEXANOX;APNTNASOL	5362737	NOV 08, 2011	U-243		
	019787	001	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	002	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	003	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	020420	001	ARBUTAMINE HYDROCHLORIDE;GENESA	5108363	APR 28, 2009	U-220		
				5234404	AUG 10, 2010	U-220		
				5395970	MAR 07, 2012			
>ADD>	020702	001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
>ADD>	020702	002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
>ADD>	020702	003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
	020114	001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 01, 2010	U-207		
	017573	001	BECLOMETHASONE DIPROPIONATE;VANCERIL	4364923	DEC 21, 1999			
	018521	001	BECLOMETHASONE DIPROPIONATE;VANCENASE	4364923	DEC 21, 1999			
	020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH	4364923	DEC 21, 1999			
	019408	001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
	020816	001	BRINZOLAMIDE;AZOPT	5240923	AUG 31, 2010	U-224	NCE	APR 01, 2003
				5378703	AUG 31, 2010	U-224		
				5461081	OCT 24, 2012	U-225		
>ADD>	020711	002	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			
>ADD>	020711	003	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			
	020554	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
	020611	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
	020313	002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U-227		
	020521	001	CALFACTANT;INFASURF				NCE	JUL 01, 2003
	020838	001	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5508297	FEB 24, 2014	U-3		
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020838	002	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5508297	FEB 24, 2014	U-3		
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020838	003	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5508297	FEB 24, 2014	U-3		
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020838	004	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5508297	FEB 24, 2014	U-3		
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020896	001	CAPECITABINE;XELODA				NCE	APR 30, 2003
	020896	002	CAPECITABINE;XELODA				NCE	APR 30, 2003
	020712	001	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
	020712	002	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
	020297	001	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	002	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	003	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	004	CARVEDILOL;COREG	5760069	JUN 07, 2015	U-233		
	020774	001	CHLORHEXIDINE GLUCONATE;PERIOCHIP				NP	MAY 15, 2001
	020238	002	CIMETIDINE;TAGAMET HB				D-41	JUN 05, 2001
	020369	001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	JUN 02, 2004	U-223	NDF	MAR 30, 2001
	020805	001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003		NC	FEB 10, 2001
				4844902	FEB 11, 2008			
	020780	001	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
	020780	002	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
>ADD>	020822	002	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
>ADD>	020822	003	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
>ADD>	020822	004	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	020839	001	CLOPIDOGREL BISULFATE;PLAVIX	4529596	JUL 05, 2003			
				4847265	FEB 12, 2008			
				5576328	JAN 31, 2014			
	017922	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	017922	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	017922	003	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	018938	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	018938	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	019955	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
	019955	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
	020713	001	DESOGESTREL;MIRCETTE				NP	APR 22, 2001
>ADD>	020809	001	DICLOFENAC SODIUM;DICLOFENAC SODIUM	5603929	NOV 16, 2014	U-239		
>ADD>				5653972	NOV 16, 2014	U-239		
	020037	001	DICLOFENAC SODIUM;VOLTAREN				I-213	FEB 25, 2001
	020148	001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL	4758423	JUL 31, 2001			
				4462983	JUL 31, 2001	U-227		
				5169849	DEC 08, 2009			
						U-227		
	020401	001	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	002	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	003	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	004	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	005	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
>ADD>	020449	001	DOCETAXEL;TAXOTERE				I-231	JUN 22, 2001
	020869	001	DORZOLAMIDE HYDROCHLORIDE;COSOPT				NC	APR 07, 2001
	020164	001	ENOXAPARIN SODIUM;LOVENOX				I-217	JAN 30, 2001
							I-222	MAR 27, 2001
	020164	002	ENOXAPARIN SODIUM;LOVENOX				I-222	MAR 27, 2001
							I-217	JAN 30, 2001

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020738	004	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3		
	020738	005	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3		
	020718	001	EPTIFIBATIDE;INTEGRILIN				NCE	MAY 18, 2003
	020718	002	EPTIFIBATIDE;INTEGRILIN				NCE	MAY 18, 2003
	020375	003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
	083209	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
	086715	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
	020363	001	FANCICLOVIR;FAMVIR				NCE	JUN 29, 1999
>ADD>	020752	001	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
>ADD>				4305502	DEC 15, 1998			
>ADD>				4371516	JAN 31, 2000	U-241		
>ADD>	020752	002	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
>ADD>				4305502	DEC 15, 1998			
>ADD>				4371516	JAN 31, 2000	U-241		
>ADD>	020786	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	4254129	APR 10, 1999		NCE	JUL 25, 2001
				5375693	AUG 03, 2012			
				5578610	NOV 26, 2013			
>ADD>	020788	001	FINASTERIDE;PROPECIA	5547957	OCT 15, 2013	U-236		
	020180	001	FINASTERIDE;PROSCAR				I-221	MAR 20, 2001
	018830	001	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	002	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	003	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	004	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018554	001	FLUTAMIDE;EULEXIN	4472382	SEP 18, 2001	U-24		
				5712251	SEP 18, 2001	U-216		
	020121	001	FLUTICASONE PROPIONATE;FLONASE				I-224	OCT 31, 2000
>ADD>	020378	001	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
>ADD>				5767251	JUN 16, 2015			
>ADD>	020378	002	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
>ADD>				5767251	JUN 16, 2015			
>ADD>	020450	001	FOSPHENYTOIN SODIUM;CEREBYX	4260769	APR 07, 2003			
	020695	001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR	5563138	OCT 08, 2013			
	020818	001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001
	020818	002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001
	020716	001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U-55		
	016295	002	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	016295	003	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	016295	004	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	020812	001	IBUPROFEN;PEDIATRIC ADVIL				NP	JUN 16, 1998
	020903	001	INTERFERON ALFA-2B;REBETRON	4530901	JUL 23, 2002		NP	JUN 03, 2001
				4211771	JUL 08, 1999	U-234		
				5767097	JAN 23, 2016	U-235		
>ADD>	020923	001	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002			
>ADD>	020923	002	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002			
>ADD>	020923	003	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002			
	020393	001	IPRATROPIUM BROMIDE;ATROVENT				I-223	APR 01, 2001
>ADD>	020657	001	ITRACONAZOLE;SPORANOX	4267179	JUN 23, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019927	001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
	020406	001	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
>ADD>							D-42	JUL 20, 2001
	020406	002	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
>ADD>							D-42	JUL 20, 2001
	020807	001	LEPIRUDIN;REFLUDAN	5180668	JAN 19, 2010		ODE	MAR 06, 2005
							NCE	MAR 06, 2003
	019732	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020011	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020517	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020263	002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020708	001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5716640	SEP 02, 2013			
	020517	002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5716640	SEP 02, 2013			
	019941	001	LIDOCAINE;EMLA				I-215	FEB 04, 2001
	020962	001	LIDOCAINE;EMLA				NP	FEB 04, 2001
	020606	001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5716641	MAY 21, 2012	U-226		
	020803	001	LOTEPREDNOL ETABONATE;ALREX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	020583	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	020841	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	019832	003	MAFENIDE ACETATE;SULFAMYLON				NDF	JUN 05, 2001
							ODE	JUN 05, 2005
>ADD>	020652	001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	JUN 12, 2007			
>ADD>				4992554	FEB 12, 2008			
>ADD>				5091169	FEB 25, 2009			
>ADD>				5223243	JUN 29, 2010	U-237		
>ADD>				4647447	MAR 03, 2004	U-238		
	019618	001	MESALAMINE;ROWASA	4657900	APR 14, 2004			
				RE33239	MAY 12, 2004			
	020208	001	METRONIDAZOLE;METROGEL-VAGINAL				D-40	MAY 16, 2000
	020827	001	MICONAZOLE NITRATE;MONISTAT 3				NP	MAR 30, 2001
	020762	001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	4472393	SEP 18, 2001			
	020830	001	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020829	002	MONTELUKAST SODIUM;SINGULAR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020763	001	NARATRIPTAN HYDROCHLORIDE;AMERGE				NCE	FEB 10, 2003
	020763	002	NARATRIPTAN HYDROCHLORIDE;AMERGE				NCE	FEB 10, 2003
	020536	001	NICOTINE;NICOTROL	4915950	FEB 12, 2008			
	020555	001	NIZATIDINE;AXID AR				I-220	APR 01, 2001
							D-39	APR 01, 2001
	020799	001	OFLOXACIN;FLOXIN				NDF	DEC 16, 2000
	019810	001	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001
	019810	002	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001
	020262	001	PACLITAXEL;TAXOL				I-226	APR 09, 2001
							I-230	JUN 30, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020819	001	PARICALCITOL;ZEMPLAR				NCE	APR 17, 2003
	020237	001	PILOCARPINE HYDROCHLORIDE;SALAGEN				ODE	FEB 11, 2005
							I-212	FEB 11, 2001
	020667	001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	019898	002	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019898	003	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019898	004	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019781	001	PROGESTERONE;PROMETRIUM				MP	MAY 14, 2001
	019627	002	PROPOFOL;DIPRIVAN	5731355	MAR 22, 2015	U-217		
				5731356	MAR 22, 2015	U-218		
	020815	001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2001			
				5393763	JUL 28, 2012	U-114		
				5457117	JUL 28, 2012	U-114		
				5478847	MAR 02, 2014	U-114		
	020520	001	RANITIDINE HYDROCHLORIDE;ZANTAC 75				I-228	JUN 08, 2001
	021024	001	RIFAPENTINE;PRIFTIN				NCE	JUN 22, 2003
							ODE	JUN 22, 2005
	020835	001	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	NCE	MAR 27, 2003
	020272	005	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009		D-37	OCT 17, 2000
>ADD>	020864	001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
>ADD>	020864	002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
>ADD>	020865	001	RIZATRIPTAN BENZOATE;MAXALT-MLT	4305502	DEC 15, 1998		NCE	JUN 29, 2003
>ADD>				5298520	JAN 28, 2012	U-240		
>ADD>				4758598	DEC 15, 1998			
>ADD>				4371516	FEB 01, 2000			
>ADD>	020865	002	RIZATRIPTAN BENZOATE;MAXALT-MLT	4305502	DEC 15, 1998		NCE	JUN 29, 2003
>ADD>				5298520	JAN 28, 2012	U-240		
>ADD>				4758598	DEC 15, 1998			
>ADD>				4371516	FEB 01, 2000			
	020772	001	SACROSIDASE;SUCRAID				ODE	APR 09, 2005
							NCE	APR 09, 2003
	020236	001	SALMETEROL XINAFOATE;SEREVENT	5126375	FEB 12, 2008		I-216	FEB 05, 2001
	020692	001	SALMETEROL XINAFOATE;SEREVENT	5225445	FEB 12, 2008	U-211		
				5380922	JAN 10, 2012			
				5590645	MAR 01, 2011			
				5126375	FEB 12, 2008			
				D342994	JAN 04, 2008			
>ADD>	020443	001	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
>ADD>				4703035	DEC 28, 2004			
>ADD>	020443	002	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
>ADD>				4703035	DEC 28, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020895	001	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	002	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	003	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	019676	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	019676	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	020181	001	SOYBEAN OIL;LIPOSYN III 30%				NP	JAN 13, 2001
	020626	001	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	020626	002	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	020626	003	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	020791	001	TESTOSTERONE;TESTODERM	4379454	FEB 17, 2001			
>ADD>	020785	001	THALIDOMIDE;THALOMID				NCE	JUL 16, 2003
>ADD>							ODE	JUL 16, 2005
	020912	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			
	020913	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			
	020697	001	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020697	002	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020771	001	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
	020771	002	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
	020137	002	TORSEMIDE;DEMADEX				D-38	FEB 13, 2001
	020528	001	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	002	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	003	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020675	001	URSODIOL;URSO	4859660	AUG 22, 2006			
	020699	001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
>ADD>	020388	001	VINORELBINE TARTRATE;NAVELBINE	4307100	JUL 08, 2002			

New 18th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
*** 80128**

Charge your order. It's easy!

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $77.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐ – ☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature) (11/97)

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____) _____
Daytime phone including area code

_____
Purchase Order No. (optional)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.